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ABSTRACT 
           Despite the evidence that alcohol and cigarette smoke have harmful effects 
on the developing fetus, alcohol consumption and smoking during pregnancy 
remains a common behavior among women. Fetal exposure to alcohol can result in 
numerous developmental abnormalities referred to as fetal alcohol spectrum 
disorder (FASD). Fetal exposure to cigarette smoke is related to premature birth and 
low birth weight for gestational age. Recent evidence suggests, however, that both 
alcohol and cigarette smoke may alter the fetal lung development and immunity and 
therefore predispose infants to respiratory infections. The purpose of this study was 
to establish new, advantageous animal models for fetal exposure to alcohol and 
nicotine; to determine if in-utero exposure to alcohol and nicotine alters fetal lung 
innate immune components, primarily surfactant proteins A and D (SP-A and SP-D, 
respectively); and finally to determine the possible mechanism by which alcohol 
alters the fetal lung development and immunity.   
In this study, we established new sheep animal models for fetal exposure to 
alcohol and nicotine. We demonstrated that exposure to low levels of alcohol during 
the last trimester of pregnancy decreases SP-A gene expression in lambs born 
prematurely and SP-A protein expression in full-term lambs. Exposure to alcohol did 
not alter SP-D protein or gene expression in pre-term or full-term lambs. In addition, 
exposure to low levels of nicotine during the last trimester of pregnancy decreases 
SP-A gene and protein expression in lambs born prematurely. Exposure to nicotine 
did not alter SP-D protein or gene expression in pre-term or full-term lambs. Finally, 
we demonstrated that alteration of SP-A expression in premature lambs exposed to 
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alcohol in-utero could be attributed to the alcohol-related decreased expression of 
vascular endothelial growth factor (VEGF) in the fetal lung.  
In conclusion, our findings indicate that fetal exposure to alcohol and nicotine 
alters the fetal lung innate immunity and development which in part may explain 
alcohol and nicotine-related increased incidence of respiratory infections in 
neonates.  
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CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation describes the effects of prenatal exposure to alcohol 
(ethanol) and nicotine on the innate immunity factors of the developing fetal lung 
using the in vivo sheep animal model. The dissertation is divided into five chapters 
that include a general introduction, three manuscripts that have been published or 
submitted for publication, and a general conclusion. Chapter 1 includes the 
dissertation overview, describes the dissertation organization, and includes: (a) a 
review of the impact of alcohol and nicotine on immunity with an emphasis on 
neonatal lung immunity and maturation; (b) a review of lung innate immunity with an 
emphasis on mucociliary clearance in the respiratory tract and pulmonary collectins; 
pulmonary surfactant protein A (SP-A), pulmonary surfactant protein D (SP-D); (c) a 
review of fetal lung development with an emphasis on lung development in sheep in 
comparison to lung development in humans and rodents; and (d) a review of 
vascular endothelial growth factor (VEGF) and its role in lung development. Chapter 
2 describes a novel sheep model for prenatal alcohol exposure that demonstrates 
that moderate alcohol exposure during the third trimester of pregnancy is associated 
with significant reduction of SP-A mRNA expression and cilia beat frequency in 
lambs born prematurely. This finding may partially explain the increased incidence of 
pulmonary infections in neonates exposed to alcohol in utero. Chapter 3 describes a 
novel sheep model for prenatal nicotine exposure that demonstrates that low-grade 
nicotine exposure during the third trimester of pregnancy significantly decreases 
SP-A mRNA and protein expression in lambs born prematurely. This finding 
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suggests a possible mechanism by which smoking during pregnancy alters fetal lung 
maturation and predisposes infants to neonatal pulmonary infections. Chapter 4 
describes the possible mechanism underlining the effect of alcohol previously 
described in Chapter 2. It also describes the influence of prenatal alcohol exposure 
on the expression of crucial pulmonary immune genes in the neonatal lung. Chapter 
5 includes the general conclusions and future plans based on findings in this 
dissertation.  
Overview 
Alcohol (ethanol) consumption and smoking remain common behavior among 
women during pregnancy despite the fact that harmful health effects to the fetus are 
widely recognized. The fetal alcohol spectrum disorder (FASD), which includes 
multiple birth defects and neurodevelopmental disorders, has been well described in 
the literature1. Little is known, however, about the effects of fetal alcohol exposure 
on fetal lung development and immunity. It has been recently suggested that fetal 
alcohol exposure alters the immunity of newborn children and predisposes them to 
bacterial infections and sepsis. Furthermore, experimental studies done in animal 
models indicate that alcohol may have a detrimental effect on neonatal lung 
immunity by impairing the function of alveolar macrophages2-4. Smoking during 
pregnancy is the leading cause of neonatal morbidity and mortality, which are 
primarily attributed to the premature birth and low birth weight for gestational age5,6. 
In addition, infants born to mothers who smoked during pregnancy have impaired 
pulmonary immunity that results in increased risk of respiratory infections such as 
respiratory syncytial virus (RSV) infection7. These data suggest that both fetal 
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alcohol and nicotine exposure may alter the lung innate immunity of neonates and, 
therefore, impair the pulmonary defense against respiratory pathogens. The 
respiratory tract innate immune system plays a crucial role in preventing the 
colonization and proliferation of inhaled microorganisms in the airways, thus 
maintaining the efficient physiological function of the lung: gas exchange. Although 
the innate immunity of the respiratory tract is a complex system that includes an 
anatomic barrier, many cellular and secretory components, mucociliary clearance, 
surfactant protein-A (SP-A), and surfactant protein-D (SP-D) represent important 
elements of pulmonary first-line defense. Once inhaled, microorganisms are trapped 
in a thin mucous layer lining the lower respiratory tract, propelled to the oropharynx 
by synchronized movement of the cilia, and expectorated. If this defense mechanism 
fails and microorganisms remain in the airways or alveoli, the cellular and secretory 
mechanisms are triggered. SP-A and SP-D are secreted by type II alveolar epithelial 
(ATII) cells and Clara cells. These are powerful antimicrobial proteins that can fight a 
broad spectrum of microorganisms such as bacteria, viruses, and fungal organisms8. 
Impaired function of mucociliary clearance and antimicrobial surfactant proteins 
opens a window of opportunity for microorganisms to reach and colonize the airways 
and alveoli. Finally, although research related to the effects of alcohol and nicotine 
on the developing fetus is broad, there is a lack of animal models that closely 
parallel the fetal development and the habits of drinking and smoking in humans. 
The purpose of the work in this dissertation is to: 
1. characterize the sheep as an animal model for maternal alcohol 
administration;  
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2. test the hypothesis that prenatal alcohol exposure in moderate levels 
during the last trimester of pregnancy alters the cilia function in the 
trachea and pulmonary SP-A and SP-D expression in neonatal lambs;  
3. characterize an ovine animal model for maternal nicotine administration;  
4. test the hypothesis that prenatal, low-grade nicotine exposure during the 
last trimester of pregnancy alters the expression of pulmonary SP-A and 
SP-D in neonatal lambs; and 
5. determine the possible mechanism by which intrauterine alcohol exposure 
alters the expression of the key innate immunity components.  
Alcohol (Ethanol) Consumption During Pregnancy 
Alcohol is the most commonly consumed chemical during pregnancy that has 
harmful effect on the developing fetus. The most recent survey, published in 2009, 
found that in the United States up to 30% of pregnant women consume alcohol at 
some point during pregnancy9. Among these women, 8.3% report binge drinking, 
2.7% report drinking during all trimesters of pregnancy, and 7.9% report drinking 
during the third trimester. Other surveys that analyzed the amount of alcohol 
consumed during pregnancy found that 5 to 10 out of 1,000 women consume seven 
or more drinks per week10-12. These alarming numbers clearly indicate that a 
significant number of neonates have been exposed to alcohol during fetal 
development.  
Effects of in-utero exposure to alcohol (ethanol) on the developing fetus  
It is well established that in-utero exposure to alcohol results in a number of 
physical, behavioral, and cognitive abnormalities in neonates, together referred to as 
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fetal alcohol spectrum disorders (FASD)1. Incidence of FASD in United States 
ranges from 7–10 cases per 1,000 live births every year13. FASD includes fetal 
alcohol syndrome (FAS), alcohol-related birth defects (ARBD), and alcohol-related 
neurodevelopmental disorders (ARND). FAS encompasses a spectrum of disorders 
including pre- and post-natal growth retardation, facial defects, and neurological, 
structural, and functional abnormalities14. In addition to the defects found in FAS, 
ARBD includes defects in other organ systems such as cardiovascular, skeletal, and 
renal14. ARND encompasses a range of cognitive, behavioral, and emotional 
abnormalities in children who were exposed to alcohol during in-utero development 
but do not have abnormalities typical of FAS14. In addition to FASD, alcohol 
consumption during pregnancy is a risk factor for premature birth and small for 
gestational age birth15,16.  
Alcohol (ethanol) and the immune system  
It is established that alcohol impairs the immune system in adults. Alcohol 
abuse in chronic alcoholics has been linked to increased incidence and severity of 
infectious diseases such as bacterial pneumonia and hepatitis C17,18. Studies done 
on humans and experimental animal models have demonstrated that both acute and 
chronic alcohol exposure results in defects of cellular components of innate and 
acquired immunity. Acute exposure to alcohol reduces expression of 
pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin 
(IL)-1β in human blood monocytes19,20. It also suppresses adhesion, migration, 
phagocytosis, and oxidative burst in polymorphonuclear leukocytes (PMN’s)21,22. In 
mice, chronic exposure to alcohol reduces lymphocyte numbers in the spleen, 
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thymus, and gut-associated lymphoid tissues, most likely through stimulation of 
apoptosis23,24. In murine natural killer (NK) cells, exposure to alcohol reduces 
expression of perforin, granzyme A, and granzyme B25. In addition, chronic exposure 
to alcohol increases production of reactive oxygen species (ROS) by Kupffer cells 
and reduces antigen presentation by antigen-presenting cells26.  
Alcohol (ethanol) and respiratory tract  
Studies of the effects of alcohol on lung immunity are limited. Epidemiological 
studies of chronic alcoholics, however, show that these individuals are at increased 
risk of developing pneumonia caused by Gram-negative bacteria, specifically 
Pseudomonas aeruginosa and Klebsiella pneumoniae17,18. This is in part due to 
suppressed swallowing reflex which can result in aspiration of oral contents; many 
studies have demonstrated, however, that alcohol directly inhibits immune cell 
responses in the lung. For example, in humans, alcohol suppress expression of 
IL-17 by T cells which stimulates recruitment of neutrophils in the lung in response to 
K. pneumoniae27,28. Intraperitoneal injection of alcohol induces suppression of lung 
chemokine production and defense against Streptococcus pneumoniae in mice29. In 
addition to PMNs, alcohol alters the function of alveolar macrophages by reducing 
expression of TNF-α, IL-1β, and CXC chemokines19. Chronic alcohol ingestion 
potentiates TNF-alpha-mediated oxidative stress and apoptosis in rat type II cells 
which are the source of SP-A and SP-D, the major components of pulmonary innate 
immunity30. In addition to SP-A and SP-D, alcohol ingestion alters airway mucociliary 
clearance, another major defense mechanism in the lung. The effect of alcohol 
mucociliary clearance depends on the length of the exposure. If acutely exposed to 
 
 
7
alcohol, the ciliary beat frequency in bovine bronchial epithelial cells increases31. In 
contrast, chronic exposure to alcohol results in decreased ciliary beat frequency32. 
This same effect of chronic alcohol exposure was demonstrated in vivo in rats and 
mice33,34.  
Alcohol (ethanol) and neonatal immunity  
Although the data on the effect of in-utero exposure to alcohol on neonates 
are limited, a few recent reports suggest that alcohol may also impair fetal 
immunity2,35. Children diagnosed with FAS commonly have increased incidence of 
infection such as meningitis, soft tissue infection, pneumonia, and sepsis36. The 
incidence of respiratory infections appears to be particularly frequent36,37. The most 
recent studies done on a guinea pig model of in-utero alcohol exposure has 
demonstrated that alcohol impairs the alveolar macrophages in neonates3. This 
impairment was attributed to the glutathione depletion in the neonatal lung by 
alcohol and subsequent increase in oxidative stress and apoptosis of alveolar 
macrophages2,38,39. In addition to alveolar macrophages, alcohol exposure reduces 
mitochondrial glutathione levels in alveolar type (ATII) cells to make ATII cells more 
susceptible to apoptosis and necrosis40. In addition, the majority of children exposed 
to alcohol in-utero do not exhibit typical changes associated with FASD, and 
consequences of alcohol impact on fetal development and immunity remain 
undiagnosed.  
Animal (ethanol) models used in alcohol research  
Rodents are the most common animal model used in alcohol research. 
Rodents are small, easy to handle, and inexpensive. Their metabolic and endocrine 
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events during pregnancy share many similarities to humans. Selective breeding has 
developed a line of rats which prefer 10% alcohol to water (Alko, Alcohol) and a line 
which chooses water over alcohol (Alko, Non-Alcohol)41. Rats can be fed with a 
special liquid diet containing alcohol (Lieber and De Carli diet) which provides 36% 
of energy from alcohol or isocaloric amounts of carbohydrate42. To completely avoid 
the reduction of weight gain due to decreased dietary intake in alcohol-fed animals, 
alcohol can be administered via an intragastric tube or intravenously43,44. The guinea 
pig is another animal model used in alcohol research. As rodents, they are easy to 
handle, inexpensive, and can receive alcohol orally4. Sheep are a commonly used 
animal model in alcohol research, especially for experiments addressing in-utero 
exposure to alcohol45-47. Although sheep are an expensive animal model, the fetus is 
large and robust, which allows easier experimental instrumental manipulation and 
handling when compared to rodents. Furthermore, the major advantage of the sheep 
model is lung development that closely corresponds to lung development in the 
human fetus, which is not the case with rodent species48,49. Sheep, however, cannot 
be administered alcohol orally due to ruminal microflora which largely degrade 
ingested alcohol before it reaches systemic circulation50. Therefore, intravenous 
administration of alcohol is the only technique that has been used to achieve chronic 
systemic alcohol exposure46,47. This approach has significant experimental 
deficiencies because intravenously administered alcohol bypasses the first pass 
hepatic metabolism, which does not resemble the physiological processing of orally 
consumed alcohol51. 
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Smoking During Pregnancy 
According to the 2006 survey conducted by the National Center for Chronic 
Disease Prevention and Health Promotion (CDC), 20.8% of adults in the United 
States are cigarette smokers, out of which 18% are women52. According to Merzel et 
al., women tend to quit smoking before or during pregnancy, and up to 85% of 
female cigarette smokers maintain cessation throughout pregnancy53. The result of 
the latest CDC survey conducted from 2001 to 2005, however, revealed that 13.8% 
of women in United States smoke during pregnancy54. These numbers indicate that 
a large group of neonates is exposed to the cigarette smoke during gestation. In the 
Unites States alone, 776 infants die annually as a result of maternal smoking during 
pregnancy55.  
Effects of in-utero exposure to cigarette smoke/nicotine on the developing 
fetus 
Cigarette smoking prior to pregnancy is a risk factor for secondary infertility56.  
Smoking during pregnancy has a wide range of negative health effects on the 
developing fetus which include obstetric complications, intra-uterine growth 
retardation, and postnatal complications57. Premature birth is the most common 
obstetric complication; it is estimated that smoking during pregnancy is responsible 
for 15% of all premature births58. Other less common obstetric complications include 
ectopic pregnancy, spontaneous abortion, and placenta previa59,60. Intra-uterine 
growth retardation is a consequence of reduced surface area and volume of the 
placenta which further results in decreased oxygen and nutrient supply to the fetus61. 
Post-natal complications include increased risk of sudden infant death syndrome 
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(SIDS), lower respiratory infections, middle ear infections, compromised lung 
function, wheezing, and asthma57.   
Cigarette smoke/nicotine and the immune system of the respiratory tract 
Cigarette smoke contains thousands of chemicals some of which are proven 
to have immunomodulatory effect62. Nicotine is an important chemical in the 
cigarette smoke due to its addictive properties and systemic effects on different 
organs63. Recent evidence indicates that nicotine modulates immunity in similar 
manner as whole cigarette smoke64-66. Exposure to cigarette smoke results in 
increased permeability and loss of cellular integrity of the airway epithelium67. In 
addition, cigarette smoke stimulates secretion of pro-inflammatory cytokines such as 
IL-8, IL-6, and TNF-α by the bronchial epithelial cells68. The increased mucus 
production in smokers is attributed to increased expression of the epidermal growth 
factor receptor (EGFR) on epithelial cells, which is the major regulator of mucus 
production in the airways69. In smokers, broncho-alveolar lavage (BAL) fluid contains 
reduced levels of SP-A compared to non-smokers, indicating that smoking affects 
the function of ATII cells70. Smoking increases the numbers of alveolar 
macrophages71; these cells, however, are less mature and have reduced capability 
to phagocyte bacteria72. Smoking increases the influx of PMNs in the airways which 
are more active and release higher levels of proteolytic enzymes73,74. Smoking also 
increases the numbers of cytotoxic T cells and decreases the ratio of CD4+/CD8+ 
ratio75. In addition, smoking elevates the number of eosinophils in the respiratory 
tract76. 
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Cigarette smoke/nicotine and neonatal immunity  
Children born to mothers who smoked during pregnancy have increased risk 
of respiratory and middle ear canal infections and increased incidence of asthma 
and wheezing77. These reports indicate that maternal smoking may alter the immune 
system in neonates. It has been reported that maternal smoking disrupts the 
antioxidant system in the placenta which further damages placental trophoblasts 
which are the source of cytokines important in regulation of fetal immunity78. 
Furthermore, maternal smoking results in decreased numbers of segmented 
neutrophils, lymphocytes, and myeloid precursor dendritic cells as well as 
immunoglobulin (Ig)E in the cord blood79,80. Neonates exposed to cigarette smoke 
in-utero have lower cytokine response upon TLR-2, TLR-3, and TLR-9 activation81. A 
study conducted in neonatal rats reported that intrauterine exposure to nicotine 
accelerates ATII cell proliferation; these cells, however, have decreased capability to 
produce pulmonary surfactant, including SP-A and SP-D82. Overall, maternal 
smoking suppresses the development of fetal immunity; few studies, however, have 
adequately addressed this particular problem.  
Animal models in cigarette smoke/nicotine research  
Rodents are the most commonly used animal models in the cigarette 
smoke/nicotine research field due to the easy exposure of caged animals to 
cigarette smoke (cigarette smoke chamber)83. Currently described sheep models in 
nicotine research utilize intravenous application and placement of subcutaneous 
infusion pumps for the long-term nicotine delivery84,85. While intravenous 
administration is less invasive, it can be associated with dosing problems due to the 
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acute bolus administration of nicotine in circulation. Subcutaneous pumps provide 
much more controlled long-term nicotine delivery; their placement, however, requires 
general anesthesia and surgery which significantly increases the cost and 
complexity of the model85.     
Innate Immunity of the Respiratory Tract 
The respiratory tract represents the largest epithelial surface of the body that 
is constantly exposed to potentially pathogenic microorganisms, toxins, aerosols, 
and particulates present in the inspired air. The innate immunity of the respiratory 
tract is the first line of defense against inhaled microorganisms and consists of three 
general components:  
1. a mechanical defense component, which includes an anatomic barrier and 
a mucociliary apparatus;  
2. a secretory component which includes a broad spectrum of anti-microbial 
agents; and  
3. a cellular component, which includes phagocytic and inflammatory cells. 
Anatomic barrier  
The respiratory epithelium lining the airways together with airway surface 
liquid (ASL) represents the physical barrier of the respiratory tract that prevents entry 
and colonization of microorganism in the deeper mucosal and submucosal tissues. 
The airway is anatomically divided into the upper respiratory and lower respiratory 
tracts. The upper respiratory tract includes nasal passages, nasal sinuses, and the 
nasopharynx. The lower respiratory tract consistis of the trachea which branches 
into the bronchi and bronchioles and terminates with alveoli86. The proximal airways 
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of the lower respiratory tract such as the trachea and bronchi are lined by 
pseudostratified columnar ciliated epithelial cells, mucus-secreting goblet cells, and 
basal cells. The smaller airway branches are lined with fewer basal cells, and 
epithelial cells are more cuboidal. The bronchoalveolar junction is lined by numerous 
non-ciliated (Clara) cells which release innate immune product such as surfactant 
proteins and metabolize toxins. Ninety-five percent of the alveolar surface is lined by 
thin, elongate epithelial cells (type I pneumocytes, ATI cells), and the rest of the 
surface is covered by cuboidal to rounded cells (type II pneumocytes, ATII cells)86. 
Individual epithelial cells are tightly joined to each other by specialized complexes 
that include gap junctions, desmosomes, adherence junctions, and zonula 
occludens or tight junctions87. These junctions form a mechanical barrier between 
the airway lumen and underlying tissue. Desmosomes mediate mechanical adhesion 
between the neighboring cells, and tight junctions encircle the cells at the apical 
membrane and completely obliterate the space between the cells88. This epithelial 
organization allows communication between neighboring cells, as well as selective 
passage of molecules such as antioxidants and components of ASL89. In addition to 
tightly joined epithelial cells, mucous and serous epithelial cells of submucosal 
glands contribute to epithelial mechanical barrier and produce ASL90.  
                                          Mucociliary Apparatus 
The mucociliary clearance is a defense mechanism by which the inhaled 
particles, including microorganisms, are expelled from the respiratory tract by 
retrograde expulsion of particulates91. It involves ciliated epithelial cells and overlying 
airway surface liquid (ASL). The inhaled particles are trapped onto a superficial, 
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sticky, mucus layer of ASL, then propelled by cilia movement into the oropharynx 
and swallowed or expectorated92. Ciliated epithelial cells line the upper respiratory 
tract from the trachea to the respiratory bronchioles93. They account for 56% of the 
total epithelial cells lining the trachea and about 15% in the lower respiratory 
bronchioles94. Each cell contains approximately 200 cilia that project from the cell 
surface into the overlying ASF. The length of cilia varies from 6 µm in the trachea to 
2 µm in the seventh-generation airways95. Each cilium is anchored to the cell by the 
basal body, which projects its striated rootlet named “basal foot” into the cell 
cytoplasm. The ciliary body contains a centrally located axoneme composed of two 
microtubules enclosed within a central sheath. The axoneme is further surrounded 
by nine microtubule doublets, thus forming the classical “9+2” microtubular 
arrangement96. The outer doublets are connected to axoneme by radial spokes (RS) 
and to each other by nexin links. Each doublet projects inner and outer dynein arms 
toward the adjacent doublet92. Cilia move (beat) in coordinated fashion through 
interaction between the dynein arms, adjacent microtubules, and axoneme powered 
by hydrolysis of adenosine triphosphate (ATP). This interaction results in sliding of 
the microtubules and restricted by radial spokes, cilia bend94. In order to remove 
mucus efficiently, there is a phase difference between beating cilia which creates a 
wave, often referred to as “metachronal wave” or “metachronism”97. The beat pattern 
consists of two main strokes, the effective stroke and recovery stroke98. The 
effective stroke is fast, and cilia are in an upright position which enables ciliary tips to 
embed into the mucus layer. The recovery stroke is slower, and cilia are slightly 
bent, thus avoiding the contact with mucus. The mechanism by which the pattern of 
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ciliary beating is regulated is not fully understood. In the human trachea, the ciliary 
beat frequency (CBF) is approximately 12–15 hertz (Hz)99, and by beating, cilia 
propel particles adhered to the mucus at a speed of 0.5mm/s100. There is a constant, 
slow rate of CBF (basal level) that requires only ATP.  
Regulation of ciliary beat frequency  
The  cilia can respond to insults by increasing the basal level of CBF which is 
primarily regulated by calcium (Ca2+) flux and cyclic adenosine monophosphate 
(cAMP)98. CBF correlates with intracellular Ca2+ ion [Ca2+] I concentration. Reduction 
in intracellular [Ca2+] I results in decreased CBF; in contrast, rise in intracellular 
[Ca2+]I increases CBF94. The intracellular [Ca2+] I levels are regulated by activation of 
P2-purinergic receptors by ATP and muscarinic receptors by acetylcholine (ACh) 
which results in the activation of phospholipase C (PLC)101. Activated PLC 
hydrolyzes phosphatidylinositol-4,5-biphosphate to inositol-1,4,5-triposphate (IP3) 
which stimulates the release of Ca2+ from the intracellular stores102. [Ca2+] I and 
diacylglycerol activate the protein kinase C (PKC) pathway103. After the release of 
[Ca2+] I from the intracellular stores, the [Ca2+] I levels are sustained by a continuous 
influx of Ca2+ from the extracellular space, which allows CBF to remain at high levels 
throughout exposure to an agonist104. It has been demonstrated that ciliated cells 
have specialized receptor channels designated as P2Xcilia, which have relatively high 
permeability to Ca2+ 105. In addition to the Ca2+, cyclic adenosine monophosphate 
(cAMP) and cyclic guanosine monophosphate (cGMP) play an important role in CBF 
regulation106-109. It was initially thought that Ca2+, cAMP, and cGMP were 
independent; newer evidence, however, indicates that all three pathways are closely 
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interconnected. Ciliated cells express Ca2+-dependent adenylate cyclase (AC) and in 
response to elevated intracellular Ca2+, AC increases cAMP110,111 through a 
calcium-calmodulin complex (Ca-CAM)112. Ca-CAM further activates nitric oxide 
synthase (NOS) which leads to activation of cAMP-dependant protein kinase (PKA) 
and cGMP-dependent protein kinase (PKG). PKA phosphorylates axoneme, which 
results in strong, short-term CBF enhancement. Axoneme phosphorylation by PKG 
results in moderate, prolonged CBF enhancement98. In addition, the ciliated 
epithelial cells express mechanoreceptors which, in response to mechanical 
stimulation, enhance CBF. Ciliated cells stimulated through mechanoreceptors 
release IP3, which stimulates an adjacent ciliated cell through intercellular gap 
junctions92.  
Airway surface liquid (ASL) 
 ASL is composed of three layers: (a) a superficial gel (mucus); (b) the 
periciliary fluid that covers the apical surface of the epithelial cells; and (c) a thin 
layer of surfactant which separates the other two layers91. The periciliary fluid is 
secreted by surface epithelial cells113. It hydrates the respiratory epithelium and 
provides a watery environment to enable ciliary movement. In addition to water, 
glycoproteins, and lipids, it also contains peptides and proteins with antimicrobial 
activity such as Immunoglobulin A, lysosome, lactoferrin, peroxidase, and 
antimicrobial peptides including defensins94,114. The depth of periciliary fluid is 
approximately 5-10 µm, which is crucial for effective ciliary function. If the periciliary 
fluid is too deep, cilia do not reach the superficial mucus layer and fail to clear it from 
the airways. If the periciliary fluid is too shallow, cilia get stuck in the mucus which 
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results in the same ineffective clearance of the airways93. These depths can be 
altered by dehydration and conditions in which there is impaired periciliary fluid such 
as cystic fibrosis115. Mucus is the superficial layer of ASL. Mucus is a 
nonhomogeneous, adhesive, viscoelastic gel that has three main functions in the 
respiratory tract: (a) it traps the inhaled particles, including microorganisms, which 
are further expelled from the respiratory tract via mucociliary clearance91,116; (b) it 
forms the mechanical barrier that protects the underlying respiratory epithelium; and 
(c) it prevents dehydration of respiratory epithelial cells117. In addition, airway mucus 
contains embedded neutrophils and macrophages, as well as antimicrobial proteins 
such as lysozyme, antiproteases, and immunoglobulins which, as indicated, have 
antimicrobial activity117. Mucus is predominantly produced by goblet cells and the 
submucosal glands95. It is composed of salts (1%), protein, glycoproteins (mucins) 
(2–3%), and water (95%). Mucins are composed of carbohydrates (70–80%), protein 
(20%), and sulfate bound to oligosaccharide side chains (1–2%)116. There are two 
principal forms of airway mucins: the secreted, gel-forming mucins that form the 
superficial mucus layer of ASF; and membrane-bound mucins, which may act as cell 
surface receptors91,116. The mucin genes (MUC genes) encode the protein 
backbone118. Epithelial cells of the human respiratory tract express at least 13 MUC 
genes that encode for membrane-associated mucins and 5 MUC genes that encode 
for gel-forming mucins119. The most important mucins that form airway mucus gel, 
however, are MUC5AC and MUC5B117. The thin surfactant layer is composed of 
phospholipids (phosphatidylcholine being the most abundant) (80%), neutral lipids 
(cholesterol being the most abundant) (12%), and surfactant proteins (8%). The 
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main function of surfactant in the airways is to preserve periciliary fluid, spread the 
mucin, and prevent cilia from entangling120.  
Consequences of compromised mucociliary clearance  
Mucociliary clearance is essential for normal lung function and pulmonary 
defense. The disrupted balance between cilia function, periciliary fluid, and mucus 
production leads to lung inflammation, damage, and infection. Mucociliary clearance 
is impaired by dehydraton, and in some genetic disorders such as primary ciliary 
dyskinesia (PCD)121,122 and cystic fibrosis(CF)115,123, often results in reoccurring or 
chronic pulmonary infections124-126. Asthma is another example of disrupted 
mucociliary apparatus in the respiratory tract127. In asthmatic patients, mucus 
hypersecretion results in obstruction of airway passages and increased incidence of 
pulmonary infections128. Other factors such as exposure to pollutants, cigarette 
smoking, and alcohol consumption may have negative effects on cilia function and 
mucus production34,95,129-131.  
Mucociliary clearance and alcohol (ethanol) 
Depending on the length of exposure, alcohol may increase or decrease CBF. 
In bovine bronchial epithelial cells (BBECs), short-term exposure to alcohol 
stimulates CBF; this stimulation is mediated through activation of both PKA via 
cAMP and PKG via NO31. When BBECs are preincubated with alcohol for 24hr, the 
stimulation of PKA with isoproterenol is abrogated32. This indicates that chronic 
exposure to alcohol down regulates CBF in ciliated epithelial cells; the effect was 
also demonstrated in vivo in mouse and rat animal models33,34.  
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Secretory component; antimicrobial factors  
The airway epithelium produces a wide range of antimicrobial factors to fight 
inhaled microorganisms and prevent respiratory tract infection8,132. The list of specific 
peptides/proteins, the cells of origin, and function is adopted and modified from the 
paper published by Grubor et al., “Collectins and cationic antimicrobial peptides,” 
Veterinary Pathology, 2006 September: 43(5):595–612. 
Lysozyme is secreted by epithelial cells of the trachea, bronchi, and 
tracheobronchial submucosal glands, as well as neutrophils, alveolar macrophages, 
and monocytes. Lysozyme is muramidase that cleaves the glycosidic bonds of the 
bacterial membrane peptidoglycans or kills the bacteria in nonenzymatic mechanism 
fashion133,134. Lactoferrin is secreted by epithelial cells of the trachea, serous cells of 
tracheobronchial submucosal glands, and neutrophils. Lactoferrin is an iron-binding 
protein that inhibits the growth of iron-requiring bacteria, and can be directly 
microbicidal through its N-terminal cationic fragment135,136. Surfactant proteins SP-A 
and SP-D are secreted by ATII and Clara cells. In addition to their antimicrobial 
activity against bacteria, viruses, and fungal organisms, they are also involved in 
immunomodulation, inflammation, and regulation of surfactant metabolism8. Anionic 
peptides (APs) are secreted by epithelial cells of the trachea, bronchi, and 
bronchioles. APs are bactericidal against Gram-positive and Gram-negative, and 
they require zinc as a cofactor for bactericidal activity137. Cationic antimicrobial 
peptides (AMPs) include α-, β-, and θ-defensins, and cathelicidins. α- and 
β-defensins are secreted by airway epithelia, neutrophils, and possibly alveolar 
epithelial cells. Θ-defensins are secreted by neutrophils, and cathelicidins are 
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secreted by airway respiratory epithelia, serous, and mucous cells of 
tracheobronchial submucosal glands and neutrophils. AMPs may potentially fight 
Gram-negative and Gram-positive bacteria, fungi, viruses, and parasites138,139. Clara 
cell secretory 10-kD protein (CC10) which plays an anti-inflammatory role in lung 
diseases is secreted by Clara cells140. Secretory peroxidases include 
lactoperoxidase (secreted by airway epithelia) and myeloperoxidase (secreted by 
neutrophils). They act on thiocyanate ions or produce oxygen radicals, which may 
have a bacteriostatic or bactericidal effect88. Secretory Immunoglobin (Ig) A is 
secreted by respiratory epithelia. The IgA play an important protective role against 
respiratory viruses141,142. Elafin is secreted by tracheal epithelial cells, Clara cells, 
ATII cells, and macrophages. Elafin is an antiproteinase that inhibits neutrophil 
elastase and other neutrophil-derived proteinases such as proteinase-3. It can inhibit 
neutrophil-mediated proteolytic tissue damage but may also act against microbial 
proteinases143. The secretory leukoprotease inhibitor (SLPI) is secreted by serous 
cells of tracheobronchial submucosal glands and Clara cells in vivo. In vitro, SLPI is 
produced by neutrophils, macrophages, monocytes, and epithelial cells of the lower 
respiratory tract, including alveolar epithelial cells. SLPI is a proteinase inhibitor and 
inhibits neutrophil elastase via the C-terminal domain144. The respiratory epithelial 
cells and neutrophils secrete Phospholipase A2 (PLA2). PLA2 is involved in 
cytokine-mediated inflammation, surfactant degradation, and anti-bactericidal 
activity, especially against Gram-positive bacteria145,146. There are many other less 
studied antimicrobial factors in the respiratory tract such as uric acid, 
aminopeptidases, proline-rich proteins, statherin, cystatin, and PLUNK8.  
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Collectins 
Collectins belong to the superfamily of Ca+-dependant lectins (C-type lectins); 
so far, nine different members have been identified. They are mannan-binding lectin 
(MBL), mannose-binding protein (MBP), collectin liver 1 (CL-L1), collectin placenta 1 
(CL-P1), collectin of 43 kD (CL-43), collectin of 46 kD (CL-46), SP-A, SP-D, 
conglutinin; and newly identified collectin kidney (CL-K1)147,148. These proteins share 
a common structure organized into four regions: Cysteine (cys)-rich N-terminus; 
followed by a collagen-like sequence; an α-helical coiled-coil neck; and C-terminus, 
which is C-type lectin region149. The C-type lectin region contains a carbohydrate 
recognition domain (CRD), which recognizes and binds glycoconjugates and lipids 
on microorganisms. This leads to agglutination or neutralization of the 
microorganism, opsonization for phagocytosis, and recruitment of inflammatory 
cells149.  
SP-A and SP-D protein structure  
As mentioned above, SP-A and SP-D share the common collectin structure. 
They are organized as oligomers assembled of monomers, which contain four 
structural domains. The first domain (N-terminus) is a short amino- and disulfide-rich 
domain of 7 (SP-A) to 25 (SP-D) amino acids. N-terminus is involved in the 
interchain interactions. The second domain (collagen-like domain) consists of 
Gly-X-Y repeats and forms fibrillar triple helix 20 (SP-A) to 46 (SP-D) nm long. The 
third domain (neck region) forms a short trimeric coiled-coil domain and links the 
collagen-like sequence to the fourth domain. The fourth domain is a C-type lectin 
region that contains a globular CRD. SP-A is the most abundant surfactant protein in 
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the lung and comprises 5.3% of the total pulmonary surfactant weight. SP-A is 
assembled as octadecamers that consist of six trimeric subunits that form a 
“bunch-of-tulips” shape. Each SP-A monomer has molecular weight of 28–36 kDa. 
SP-D is assembled as dodecamers that contain four homotrimeric subunits arranged 
in a cruciform shape. Each SP-D monomer has molecular weight of 43 kDa150. 
SP-A and SP-D receptors  
Little is known about collectin receptors. Several SP-A receptors have been 
identified, including the C1q receptor (also known as CD93), the calreticulin-CD91 
complex, the signal-inhibitory regulatory protein-α (SIRP-α), the 210-kDa cell surface 
protein (SP-R210) and gp-340. SP-D binds the calreticulin-CD91 complex, SIRP-α, 
and SP-R210 and gp-340150. Binding of SP-A to a certain receptor is regulated by 
the presence or absence of pathogens. For example, in the absence of potential 
pathogens, SP-A binds to SIRP-α receptor, which leads to inhibition of inflammatory 
mediators. In contrast, in the presence of pathogens SP-A binds to the 
calreticulin-CD91 complex through a free collagen-like region, thus activates 
immune cells and enhances production of inflammatory mediators such as TNF-α151. 
It has only recently been demonstrated that SP-A and SP-D suppress alveolar 
macrophage phagocytosis via interaction with SIRP alpha receptor152. The SP-R210 
receptor is localized on the cell surface of ATII cells and macrophages. Binding of 
SP-A to SP-R210 results in SP-A-mediated uptake and killing of Mycobacterium 
bovis, and inhibition of phospholipid secretion153,154. Both SP-A and SP-D bind to the 
gp-340 receptor, which has a soluble form and macrophage membrane-bound form. 
Activation of gp-340 receptor leads to binding and aggregation of some bacteria 
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such as Streptococcus mutans155. Other recent studies have demonstrated that 
SP-A and SP-D bind TLRs such as TLR-2 and TLR-4156,157. 
Biological activities of SP-A and SP-D  
SP-A and SP-D have several functional roles in the lung such as defense 
against invading microorganisms, regulation of inflammation, regulation of 
pulmonary surfactant homeostasis, and immunomodulation8. The focus of this 
section will be the antimicrobial role of SP-A. These collectins bind a wide range of 
potentially pathogenic viruses, Gram-negative and Gram-positive bacteria, and fungi 
through CRD, which leads to agglutination, enhancement of phagocytosis, and 
respiratory burst, or direct bacteriostatic and fungistatic effect150. Collectins have the 
ability to bind to enveloped viruses such as influenza A virus (IAV), respiratory 
syncytial virus (RSV), human immunodeficiency virus (HIV), and herpes simplex 
virus154,158,159. Both SP-A and SP-D suppress IAV infectivity through agglutination160. 
SP-A neutralizes IAV by binding and blocking hemagglutinin (HA) cell attachment 
site expressed on viral surface161. SP-A can also opsonize IAV and enhance 
phagocytosis by macrophages162. In addition, preincubation of IAV with SP-A 
enhances the respiratory burst of neutrophils, which phagocytes the virus160. SP-D 
causes massive agglutination of IAV particles and thus represents more potent 
collectin in suppression of this virus. SP-D binds to high-mannose oligosaccharides 
of IAV which are  present on the coat HA163. In addition, SP-D enhances the uptake 
of IAV by neutrophils, which results in protection of the neutrophils from 
virus-induced suppression and enhances respiratory burst163. SP-A and SP-D 
opsonize RSV by binding to the F (fusion) and G (adherence) protein in 
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Ca+--dependent manner159,164. Binding of SP-A to RSV enhances viral uptake by 
peripheral blood mononuclear cells and macrophages159. Both SP-A and SP-D bind 
to a broad spectrum of Gram-negative and Gram-positive bacteria, which may 
results in agglutination, permeabilization of bacterial walls, enhancement of 
respiratory burst by neutrophils, and macrophages and enhancement of 
opsonization158,165. Lipopolysacharide (LPS) represents the most common ligand for 
binding the Gram-negative bacteria while lipoteichoic acid (LTA) and peptidoglycans 
represent the most common ligand for binding G-positive bacteria. SP-A binds the 
following bacterial organisms: Staphylococcus aureus166, Pseudomonas aeruginosa, 
Escherichia coli J5 (containing O-antigen deficient rough LPS)165, Mycobacterium 
tuberculosis167, Streptococcous pneumonia, Group A and Group B Streptococci, 
Hemophilus influenzae168, and Klebsiella pneumoniae169. SP-D binds 
Mycobacterium tuberculosis, Pseudomonas aeruginosa, E.coli, and acapsular 
Klebsiella pneumoniae147. Binding of SP-A and SP-D to the same pathogen may 
have a different effect; upon binding to Mycobacterium tuberculosis, SP-D 
decreases the bacterial uptake by macrophages. In contrast, SP-A binding to the 
same pathogen enhances the bacterial uptake by macrophages167,170. Both SP-A 
and SP-D represent the major defense mechanism against inhaled fungal spores 
and yeast. The polysaccharides and highly glycosylated proteins on the fungal spore 
represent the ligands for SP-A and SP-D binding. Both SP-A and SP-D bind the 
following fungal and yeast organisms: Saccharomyces cerevisiae, Aspergillus 
fumigatus, acapsular Cryptococcus neoformans, and Pneumocystis carinii147. SP-A 
and SP-D are capable of regulating inflammatory response by stimulating an 
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anti-inflammatory and/or pro-inflammatory effect8. For example, SP-A interacts with 
macrophages through binding the CD14 receptor, inhibits the binding of smooth LPS 
to CD14, and reduces TNFα-expression induced by smooth LPS. In contrast, SP-A 
increases the inflammatory response of macrophages induced by rough LPS171. 
SP-D upregulates expression of pro-inflammatory cytokines such as IL-1,IL-6, and 
TNFα by epithelial cells upon stimulation by bacteria172. Lung collectins play a 
significant role in immunomodulation. For example, SP-D inhibits production of IL-2 
by monocytes and consequently suppresses lymphocyte proliferation172. SP-A can 
also inhibit lymphocyte proliferation through modulation of IL-2 production155. SP-D 
modulates the inflammatory response to inhaled allergens by inhibition binding of 
IgE to those allergens173. Primarily SP-A and, to a lesser extent, SP-D regulate 
surfactant homeostasis by controlling the secretion and uptake of surfactant by ATII. 
In addition, SP-A and SP-D protect surfactant from functional inhibitors such as 
phospholipase A1, and they are required for the formation of tubular myelin153.  
SP-A and SP-D metabolism  
SP-A and SP-D are synthesized by ATII and Clara cells174. After synthesis in 
endoplasmic reticulum (ER), lung collectins are transported into the Golgi apparatus 
(GA) and stored in the cytoplasmic structures named lamellar bodies (LBs)175. Upon 
stimulation, LBs are secreted via exocytosis into the alveolar space. Once they 
reach the alveolar space, LBs swell and unravel, forming a cross-hatched structure 
named tubular myelin (TM). In addition to surfactant proteins, TM contains surfactant 
lipids that create a thin surface film which reduces surface tension in the alveoli 
during the breathing cycle175. Recently, some studies have demonstrated that SP-A 
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and SP-D trafficking bypasses the LBs and that these two collectins are directly 
excreted from the GA into the alveolar space176,177. In addition, ATII cells use 
intracellular glycogen during the synthesis of surfactant phospholipids (28). 
Therefore, intracellular glycogen stores can be an indicator of ATII cell function and 
maturation178. The half-life of lung collectins is short. In rabbits, the half-life of soluble 
SP-A after the intratracheal installation into the lung is only 4.5–6.5 hours179,180. 
Collectins secreted into the alveolar space are partially internalized and degraded by 
macrophages and partially reuptaken by ATII cells and recycled181,182.  
In-utero lung development and regulation of SP-A and SP-D expression  
In the neonatal lung, the expression of SP-A and SP-D is developmentally 
regulated and primarily depends on the level of differentiation and maturation of ATII 
cells177.  
 In-utero Lung Development 
Stages of fetal lung development include the pseudoglandular, canalicular, 
saccular, and alveolar phase183. In humans, the pseudoglandular phase of lung 
development occurs from the 6th to the 16th week of gestation. This phase is 
characterized by extensive branching of the airways. The epithelial cells of the distal 
airways, including alveolar epithelial cells, are largely undifferentiated, however183. 
The canalicular phase occurs from the 16th to the 24th week of gestation. This phase 
is characterized by the remodeling of the distal portion of the branching airways and 
differentiation of alveolar epithelium. Low numbers of ATII cells are present; they are 
characterized by small, intracellular glycogen pools and few lamellar bodies. The 
saccular phase occurs from the 24th to the 36th week of gestation. During this stage, 
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the terminal airway branches develop into the terminal sacks and, to some extent, 
alveoli. These alveoli form a thin air-blood barrier, and surfactant production starts. 
The alveolar phase occurs at the 36th week of gestation and ends at approximately 
two years of post-natal age. This phase is characterized by extensive alveolar 
development that includes three stages: secondary septation, remodeling of the 
alveolar walls, and alveolar growth. During the alveolar phase, the alveoli continue to 
develop from the terminal sacks, the alveolar walls become thinner, and the 
numbers of ATII cells increase and mature. The lung development in other 
mammalian species parallels the lung development in humans; some substantial 
differences, however, are present. At birth, the lungs of mice are at the saccular 
phase, and alveolarization does not start until post-natal day 548. Similarly, the 
alveolar phase in the rat lungs starts at post-natal day 4 and continues until day 
14184. Unlike humans, guinea pigs and rabbits develop the majority of their alveoli 
prior to birth185. The development of lungs in sheep closely parallels the 
development of human lungs with the exception of the secondary septation stage of 
alveolarization, which occurs earlier in gestation. SP-A and SP-D in the fetal lung 
parallels the fetal development and maturation of ATII cells. In the human lung, SP-A 
is first detectable at the 30th week of gestation (term~40 weeks), while SP-D is first 
detectable in the second trimester of gestation186,187. In sheep, the SP-A mRNA 
levels are low at the 100th day of gestation (term~148) and progressively increase 
starting at about 120 days of gestation to term and into the postnatal period177.  
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Regulation of SP-A and SP-D expression 
In addition to gestational development, SP-A and SP-D expression is also 
regulated by a number of growth factors, hormones, and regulatory substances, 
including glucocorticoids, insulin, and vascular endothelial growth factor (VEGF) 8. 
Glucocorticoids are increasingly produced by the fetal adrenal cortex during the late 
gestation period which parallels maturation of the fetal lung. In general, 
glucocorticoids increase production of surfactant phospholipids and surfactant 
proteins and thus prevent neonates from developing respiratory distress syndrome 
(RDS)188. Interestingly, if given for prolonged time and in high concentrations, 
glucocorticoids suppress surfactant protein expression in the lung189. Insulin 
decreases the expression of SP-D in the human fetal lung, and neonates from 
diabetic mothers are at increased risk to develop RDS due to insufficient pulmonary 
surfactant190. The growth factors involved in fetal lung maturation include VEGF, 
platelet-derived growth factor (PDGF), keratinocyte growth factor (KGF), and 
transforming growth factor-beta1 (TGF-β1)183. The effects of the VEGF on the ATII 
cell maturation will be described in detail later. The PDGF-A family represents an 
important regulator of lung maturation, and mice in which the PDGF-A gene is 
deleted die soon after birth due to respiratory distress191. In addition, PDGF-A 
regulates post-natal lung development as well, and PDGF-A-/- mice fail to form 
alveoli192. KGF is a stimulator of epithelial cell proliferation and surfactant protein 
gene expression. When adult rats were inoculated intrabronchially with 5 mg/kg 
KGF, SP-A and SP-D mRNA levels were increased in the lung193. This was 
attributed mainly to the ATII cell hyperplasia while expression of SP-A and SP-D per 
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cell remained at the same level. In vitro studies done on rat ATII cells treated with 
KGF demonstrated increased expression of SP-A but did not influence expression of 
SP-D mRNA194. TGF-β1 reduces SP-A mRNA expression and impairs the 
pseudoglandular stage of fetal lung development in mice. Other factors involved in 
lung maturation and surfactant protein expression include cAMP, IFN-γ, TNF-α, IL-4, 
O2, NO, all-trans retinoic acid (RA), and  phorbol myristyl acetate (PMA)8.   
SP-A and SP-D deficiency 
Respiratory distress syndrome (RDS), characterized by a severe deficiency of 
pulmonary surfactant, is the most common complication of neonates born 
prematurely195. Pulmonary surfactant primarily functions to regulate the size of 
alveolar spaces and allows efficient respiration. SP-A and SP-D contribute to the 
lung stability to a minor extent; they, however, play a major role in pulmonary 
defense against potentially pathogenic microorganisms. The increased incidence of 
RSV infection in prematurely born neonates is in part attributed to the decreased 
levels of SP-A and SP-D in immature lungs196,197. In fact, a study done on the lamb 
model of RSV infection has demonstrated reduced viral clearance from the lungs of 
lambs born prematurely198. Furthermore, several studies done on mice deficient in 
SP-A (SP-A-/-) or SP-D (SP-D-/-) have clearly demonstrated the crucial 
immunological role of these two collectins in the lung. Mice deficient in SP-A and 
SP-D had normal pulmonary function; the pulmonary defense against different 
viruses and bacteria, however, was significantly impaired. The SP-A-/- mice had an 
increased load of bacterial organisms in the lung following the intratracheal 
installation of B streptococcus (GBS)199. The alveolar macrophages of SP-A-/- mice 
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had a reduced rate of phagocytosis of intratracheally administered Pseudomonas 
aeruginosa bacterial organisms200. Similarly, the alveolar macrophages of mice 
deficient in SP-A and SP-D demonstrated a reduced rate of phagocytosis of 
Hemophilus influenza and GBS201. SP-A-/- mice have demonstrated an increased 
susceptibility to RSV, and an intratracheal installation of SP-A enhanced the viral 
clearance from the lung202. The following study demonstrates that administration of 
SP-D to the mice infected with RSV enhanced the viral clearance from the lung203. 
Finally, SP-D-/- mice have demonstrated reduced clearance of IAV and, as in a 
previous study, intratracheal installation of SP-D enhanced the viral clearance from 
the lung204. In conclusion, the major role of SP-A and SP-D in the lung is defense 
against pathogenic microorganisms; deficiency of these two lung collectins 
enhances susceptibility of the lung to pathogenic bacterial and viral agents. In 
addition, Individuals with polymorphisms in SP-A and SP-D genes have increased 
incidence and severity of RSV infections205,206.  
Lung surfactant replacement therapies  
Therapies used to improve pulmonary function in infants deficient in 
pulmonary surfactant due to immaturity include oxygen administration, mechanical 
ventilation, and administration of exogenous glucocorticoids and pulmonary 
surfactants. Exogenous administration of glucocorticoids to the mother accelerates 
fetal lung maturation primarily through stimulation of ATII cell differentiation and 
surfactant production207,208. Therefore, administration of glucocorticoids to pregnant 
women who are at increased risk of pre-term delivery is a common medical 
practice209. Fetal exposure to exogenously delivered glucocorticoids is associated 
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with many undesirable effects. Short-term side effects include hypertension, 
hyperglycemia, intestinal perforation and bleeding, inhibition of stomach growth, and 
hypertrophic cardiomyopathy210,211. Long-term side effects include inhibition of lung 
growth and neurodevelopmental abnormalities212. In addition, surfactant protein 
expression in the lung is suppressed by prolonged glucocorticoid treatment189. 
Exogenous surfactant replacement is another treatment therapy for 
prematurity-related surfactant deficiency213. Although exogenously administered lung 
surfactant does not accelerate the process of lung maturation, it does reduce 
morbidity and mortality rates in prematurely born neonates. Most of the replacement 
surfactants used today, however, are synthetic and contain lipids, surfactant 
protein-B (SP-B), and surfactant protein-C (SP-C)214. It has only recently been 
suggested that natural surfactants, which also contain SP-A and SP-D, may be 
beneficial in treating RDS but also non-RSD respiratory disorders such as 
pneumonia and bronchiolitis214. In addition, exogenous surfactant therapy is a 
short-term therapy, and the procedure needs to be frequently repeated215. In 
summary, despite the beneficial effects of exogenously administered glucocorticoids 
and pulmonary surfactants in neonates with inadequate respiratory function, both of 
these treatments have undesirable effects or questionable efficacy, which indicates 
a need for new, more efficient therapies.  
Cellular component; phagocytic and inflammatory cells   
Under normal conditions, pulmonary macrophages are the largest population 
of the phagocytic cells in the lung88. Most of the pulmonary macrophages reside in 
the alveoli, and thus are designated as pulmonary alveolar macrophages (PAMs). 
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The main function of PAMs is to phagocytose particulate matter or bacteria that have 
reached the alveolar space by evading the mucociliary escalator and antimicrobial 
factors in the airways216. They express several recognition receptors including 
pattern recognition receptors (PRRs) such as Dectin-1, scavenger receptors, 
Toll-like receptors (TLRs), and NOD-like receptors (NLRs). Other 
macrophage-surface receptors include Fc-γ receptor, complement receptors (CR-1, 
CR-3, and CR-4), and CD40 receptors217-221. Once the particulate matter or 
microorganism is engulfed, the phagosome fuses with lysosomes which eliminate 
the phagocytized particles from the alveolar space. PAMs regulate the inflammatory 
response in the lung by secreting cytokines such as interleukin (IL)-1β, IL-6, IL-10, 
IL-12, and tumor necrosis factor (TNF-α); chemokines such as IL-8; monocyte 
chemotactic protein (MCP)-1, and MCP-2; macrophage inflammatory protein 
(MIP-1α); and MIP-1β; as well as most of the components of the complement 
pathway88. Compared to other tissue macrophages, PAMs induce minimal 
inflammatory response in order to protect pulmonary tissue from the destructive 
consequences of fulminant inflammation. This anti-inflammatory state is displayed 
through altered cytokine response such as increased expression of 
anti-inflammatory cytokine, IL-10, and reduced oxidant production222,223. In addition, 
PAMs secrete antimicrobial factors such as lysozyme and participate in humoral 
innate immunity of the lung224. If the humoral responses and macrophages are 
unable to control infectious agents, a massive flux of neutrophils occurs. In these 
circumstances, neutrophils can constitute up to 80% of the cells retrieved from the 
alveolar lavage fluid225. Chemotaxis is stimulated primarily by IL-8 secreted by 
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epithelial cells or complement activation. Neutrophils are powerful phagocytic cells; 
in addition to phagocytosis, they secrete cytokines such as IL-1β, IL-6, and TNF-α 
as well as defensins225. Under normal conditions, eosinophils are present in the low 
numbers in the lung. Upon the stimulation of T-cell derived cytokines such as IL-3, 
IL-5, as well as GM-CSF, however, they proliferate. They are involved in 
inflammatory responses against parasitic agents and allergens. Pathologic 
conditions such as asthma and chronic eosinophilic pneumonia are characterized by 
eosinophilic inflammation88. Natural killer (NK) cells respond to viruses by lysing the 
infected cells, releasing interferon (IFN)-γ, and recruiting other inflammatory cells225.  
Other innate immunity mechanisms and factors  
The innate immunity of the lungs involves many other mechanisms and 
factors that are beyond the scope of this dissertation and therefore will be outlined 
only briefly. These include complement cascade; antioxidants such as superoxide 
dismutase, catalase, glutathione peroxidase, and oxidant free radical scavengers; 
modified epithelial cells (M cells); bronchial associated lymphoid tissue (BALT); 
antiproteinases; and neurokinins.  
Vascular Endothelial Growth Factor (VEGF) 
Vascular endothelial growth factor (VEGF) refers to a large superfamily of 
growth factors primarily involved in growth of blood vessels and lymphatic 
vessels226. The VEGF superfamily includes five subfamilies of polypeptides named 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PLGF)227,228. The 
VEGF-A and VEGF-B family members regulate formation and maintenance of blood 
vessels while VEGF-C and VEGF-D family members are involved in formation and 
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maintenance of lymphatic vessels229. The VEGF-A family members are the most 
intensively studied VEGF growth factors in the past decade and hereafter will be 
referred to as VEGF.  
Biological activities of VEGF 
The VEGF polypeptides have a fundamental role in physiological 
vasculogenesis (de novo formation of blood vessels during embryogenesis), 
physiological angiogenesis (formation of blood vessels from pre-existing 
vasculature)230, and growth of blood vessels in pathological processes such as 
retinal neovascularization231, age-related macular degeneration232, rheumatoid 
arthritis233, and neoplasia234-236. The VEGF stimulates blood vessel development by 
two major mechanisms. First, it simulates proliferation of endothelial cells derived 
from both arterial and venous blood vessels227. Second, it prevents apoptosis of 
vascular endothelial cells by activating phosphatidylinositol (PI)-3-kinase-Akt 
pathway237 and anti-apoptotic proteins Bcl-2 and A1238. In addition to vascular 
endothelial cells, VEGF exerts its biological effect on many other non-endothelial 
cells, stimulates proliferation of airway epithelial cells in the human fetal lung30, 
promotes monocyte chemotaxis239, induces granulocyte-macrophage progenitor cell 
colony formation240, inhibits dendritic cell development241, and stimulates production 
of myeloid cells and B cells242. VEGF also regulates inflammation by inducing 
vascular leakage243,244 and synthesis of nitric oxide (NO) and prostacyclin (PGI2) by 
endothelial cells245.  
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VEGF isoforms  
The VEGF gene is mapped to chromosome 6p21.3 in humans and organized 
as eight exons separated by seven introns246. Due to alternative exon splicing, this 
single gene encodes for several isoforms. In humans, there are seven known VEGF 
isoforms composed of 121, 145, 148, 165, 183, 189, and 206 amino acid 
residues228. There are four analog murine isoforms composed of 120, 144, 164, and 
188 amino acid residues228, and three analog ovine isoforms composed of 120, 164, 
and 187 amino acid residues247. The VEGF isoforms are named as VEGFxxx in 
which the xxx subscript refers to the number of amino acid residues present in the 
molecule. These isoforms are glycosylated, dimeric polypeptides which may or may 
not bind heparin sulphate proteoglycans. VEGF121 is an acidic, diffusible polypeptide 
that does not bind heparin248. In contrast, VEGF189 and VEGF206 are highly basic 
polypeptides which bind to heparin with high affinity and remain sequestered on the 
cell surface upon secretion248. VEGF165 is an intermediate isoform and upon 
secretion partially remains bound to the cell surface and partially diffuses into the 
extracellular space249. Although the biological significance of different VEGF 
isoforms is not clear, some studies suggest that VEGF165 has maximal availability 
and bioactivity249.  
Regulation of VEGF expression  
Oxygen tension is the key regulator of VEGF expression. The tissue 
oxygenation regulates the VEGF expression through the actions of thee transcription 
factors: hypoxia-inducible factor 1α, 2α, and 3α (HIF-1α, HIF-2α, and HIF-3α, 
respectively)227. HIF-1α and HIF-2α upregulate the expression of VEGF; in contrast, 
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HIF-3α is considered to be a negative regulator of VEGF expression250. HIFs are 
heterodimers composed of constitutively expressed beta subunit (the aryl 
hydrocarbon receptor nuclear translocator, Arnt) and one out of three 
oxygen-sensitive subunits alpha (HIF-1α, HIF-2α, or HIF-3α)250. Under normoxic 
conditions, the alpha subunit is rapidly hydrolyzed by prolyl hydroxylase, further 
associated with von Hippel-Lindau (VHL) protein, and thereafter degraded in 
ubiquitin pathway. In hypoxic conditions, the prolyl hydroxylase is inactive, and an 
alpha subunit dimerizes with a beta subunit to form the active HIF transcription 
factor. The active forms of HIF-1α and HIF-2α bind to the promoter on the VEGF 
gene and upregulates the VEGF mRNA transcription230. Although little is known 
about HIF-3α, some studies suggest that there is a splice variant of HIF-3α gene 
known as Per/Arnt/Sim (IPAS). This HIF transcription factor does not have 
transactivation function and is reportedly a negative regulator of VEGF 
expression250. In addition to oxygen tension and oxygen-sensitive transcription 
factors, several growth factors including epidermal growth factor (EGF), transforming 
growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), fibroblast 
growth factor (FGF), and platelet growth factor (PGF) upregulate transcription of 
VEGF mRNA228,251. There is evidence that inflammatory cytokines such as 
interleukin 1alpha (IL-1α) and interleukin 6 (IL-6) upregulate transcription of VEGF 
mRNA in several cell types, thus demonstrating that VEGF is a mediator of 
angiogenesis in inflammatory conditions251. In addition, several studies indicate that 
oncogenes induce angiogenesis and progressive tumor growth mediated by 
VEGF252,253. 
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VEGF receptors  
VEGF binds three related tyrosine kinase receptors: vascular endothelial 
growth factor receptor 1, 2, and 3 (VEGFR-1, VEGFR-2, and VEGFR-3, 
respectively). VEGF-A family members bind to VEGFR-1 and VEGFR-2 to promote 
development of blood vessels227, whereas VEGF-C and VEGF-D members bind to 
VEGFR-3 to promote development of lymphatic vessels230. VEGFR-2 plays a key 
role in VEGF-mediated effects on endothelial cells such as proliferation, NO 
synthesis, and vascular permeability254,255. VEGFR-2 has an extracellular region 
composed of seven immunoglobulin-like extracellular domains, a single 
transmembrane spanning region, and an intracellular tyrosine kinase region 
interrupted by tyrosine kinase-insert domain256,257. Upon ligand binding, the tyrosine 
residues of the tyrosine kinase-insert domain undergo autophosphorylation, and 
phosphotyrosines further bind proteins containing the Src homology-2 domain258. 
This ultimately leads to endothelial cell proliferation mediated by Erk pathway258, 
endothelial cell survival mediated by 3-kinase/Akt pathway259 and caspase 9260, and 
Bad inactivation261, NO production mediated by NO synthase activation262, 
endothelial cell migration mediated by p38MAPK and paxillin263, and blood vessel 
permeability mediated by Yes tyrosine kinase264. VEGFR-1 is structurally similar to 
the VEGFR-2. Binding of VEGF to VEGFR-1, however, leads to weak 
autophosphorylation of tyrosine residues on tyrosine kinase-insert domain resulting 
in weak downstream signaling265. In addition, recent studies suggest that there is a 
soluble form of VEGFR-1, named the VEGF “decoy” receptor. The soluble form of 
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VEGFR-1 binds VEGF with high affinity and prevents VEGF from binding and 
activation of VEGFR-2266.  
The roles of VEGF, HIF and VEGFR in the lung development  
In the developing lung, VEGF primarily stimulates blood vessel growth and 
branching258. Recently it has been suggested that in addition to vasculature 
development, VEGF stimulates proliferation of alveolar type II cells (ATII cells) as 
well as production of lung surfactant proteins by ATII cells, thus accelerating lung 
maturation30,258,267-269. In the human lung, ATII cells are the major source of 
VEGF270, and VEGF levels are higher in broncho-alveolar fluid compared to the 
blood, suggesting that ATII cells themselves represent the target for VEGF271. Thus, 
addition of exogenous VEGF to the human fetal lung explants resulted in increased 
proliferation of distal airway epithelial cells30. When added to the cell culture, VEGF 
stimulated expression of SP-A and SP-C in human fetal ATII cells267. Furthermore, 
inhibition of VEGF resulted in respiratory distress syndrome (RDS) in neonatal mice 
due to insufficient production of pulmonary surfactant by ATII cells268. The exact 
mechanism by which VEGF stimulates pulmonary surfactant production is not clear; 
in the study done by Comprenolle et al., however, mice deficient in pulmonary 
surfactant had increased glycogen stores in ATII cells, indicating that VEGF 
mediates conversion of glycogen into pulmonary surfactant268. While the roles of 
specific VEGF isoforms in the lung are not fully explored, some studies suggest that 
VEGF120, VEGF164, and, in part, VEGF188,  play the most significant roles during 
intrauterine lung development272. As previously mentioned, VEGF expression is 
tightly regulated by three hypoxia-sensitive transcription factors (HIF-1α, HIF-2α, and 
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HIF-3α)227, and all three transcription factors are expressed in the developing human 
lung250. Several studies have demonstrated that HIF-1α and HIF-2α are crucial for 
intrauterine lung development and play a significant role in proliferation and 
maturation of ATII cells through VEGF action; the role of HIF-3α in lung 
development, however, is less clarified. For example, HIF-2α gene deletion in 
neonatal mice resulted in respiratory failure and death due to impaired differentiation 
of ATII cells and lack of pulmonary surfactant production268. In the same study, 
intrauterine delivery or postnatal intratracheal delivery of VEGF stimulated 
conversion of glycogen to surfactant and rescued HIF-2α-/- from respiratory failure. In 
another study done in mice, HIF-1α gene deletion resulted in impaired alveolar 
epithelial differentiation and complete loss of surfactant production, indicating similar 
roles of HIF-1α and HIF-2α in neonatal lung development273. Furthermore, RDS in 
pre-term lambs characterized by impaired pulmonary surfactant production in 
immature lungs was associated with decreased expression of both HIF-1α and 
HIF-2α274. VEGF binds two tyrosine kinase receptors: VEGFR-1 and VEGFR-2. As 
stated above, VEGFR-2 is considered the main signaling receptor for VEGF230. 
Several studies demonstrated that ATII cells express VEGFR-230,268,275, and 
intrauterine delivery of anti-VEGFR-2 antibodies in fetal mice resulted in respiratory 
failure compatible with VEGF deficiency268. In rats, chronic inhibition of VEGFR-2 
with SU5146 VEGFR-2 blocker resulted in alveolar epithelial cell apoptosis and 
pulmonary emphysema276. The data on VEGFR-1 are conflicting. The recent studies 
suggest that VEGFR-1 may serve as a “decoy” receptor for VEGF and a negative 
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regulator of VEGF signaling; VEGFR inhibition with a combined VEGFR-1 and 
VEGFR-2 inhibitor, however, reduced alveolarization in the neonatal rats277.  
VEGF and alcohol (ethanol)  
The data analyzing the influence of alcohol on VEGF are limited. I have not 
been able to identify publications that report the influence of alcohol on VEGF in 
either the adult lung or the fetal lung. Exposure to alcohol, however, has been 
associated with increased morbidity and mortality in trauma patients due to delayed 
process of wound healing. Radek et al. have demonstrated that angiogenesis, a 
crucial step in wound healing, was reduced by 61% in rats acutely exposed to 
alcohol278. The following study reveals that the mechanism by which alcohol alters 
wound healing involves an HIF-VEGF-VEGFR pathway as protein levels of HIF-1α 
and VEGFR-2 were decreased in alcohol-treated endothelial cells and VEGFR-2 
was less responsive to VEGF treatment279. There are studies that describe the 
opposite effect of alcohol on angiogenesis and VEGF in neoplastic tissues. For 
example, exposure to alcohol stimulated expression of VEGF and angiogenesis in 
mice implanted with melanoma cells, which stimulated proliferation and metastasis 
of neoplastic cells280. In another study, exposure to alcohol stimulated VEGF 
expression and angiogenesis of human fibrosarcoma cells implanted in chick 
chorioallantoic membrane281. Although there is evidence that alcohol may stimulate 
expression of VEGF, these studies are conducted in neoplastic tissues, which may 
not compare to the physiologically healthy tissues.  
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The specific goals of this dissertation were to: 
1. characterize an ovine model of fetal exposure to alcohol (ethanol) and 
nicotine,  
2. determine the effect of in utero exposure of alcohol (ethanol) and nicotine 
on pulmonary SP-A and SP-D in lambs born prematurely and lambs that 
have reached full gestation, and  
3. determine the mechanism by which in utero alcohol (ethanol) exposure 
alters the expression of pulmonary SP-A and SP-D in neonatal lambs.  
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 CHAPTER 2. MATERNAL ALCOHOL INGESTION REDUCES SP-A  
           EXPRESSION BY PRE-TERM FETAL LUNG EPITHELIA  
                                 A paper published in Alcohol 
                                      2007; Vol . 41(5):347-355. 
Tatjana Lazic, Todd A Wyatt, Milan Matic, David K Meyerholz, Branka 
Grubor, Jack M Gallup, Karl W Kersting, Paula M Imerman,  
Marcia Almeida-De-Macedo, Mark R Ackermann 
 
Abstract 
In addition to neurodevelopmental effects, alcohol consumption during 
pregnancy is associated with immunomodulation and premature birth. Premature 
birth, in turn, is associated with increased susceptibility to various infectious agents 
such as Respiratory Syncytial Virus (RSV). The initial line of pulmonary innate 
defense includes the mucociliary apparatus, which expels microorganisms trapped 
within the airway secretions. Surfactant proteins A and D (SP-A and SP-D, 
respectively) are additional components of pulmonary innate immunity and have an 
important role in pulmonary defense against inhaled pathogens. The purpose of this 
study was to determine if chronic alcohol consumption during the third trimester of 
pregnancy alters the function of the mucociliary apparatus and expression of SP-A 
and/or SP-D of fetal lung epithelia. Sixteen date-mated ewes were assigned to two 
different groups: an ethanol exposed group in which ewes received ethanol through 
surgically implanted intra-abomasal cannula during the third trimester of pregnancy, 
and a control group in which ewes received the equivalent amount of water instead 
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of ethanol. Within these two groups, ewes were further randomly assigned to a 
full-term group in which the lambs were naturally delivered, and a pre-term group in 
which the lambs were delivered prematurely via an abdominal incision and 
uterotomy. Ethanol was administered 5 times a week as a 40% solution at 1gr/kg of 
body weight. The mean maternal serum alcohol concentration (SAC) measured 6 hr 
post administration was 16.3 +/- 4.36 mg/dL. Tracheas from 6 full-term lambs were 
collected to assess ciliary beat frequency (CBF). The lung tissue from all (24) lambs 
was collected for immunohistochemistry (IHC) analysis of SP-A and SP-D protein 
production and fluorogenic real-time quantitative polymerase chain reaction analysis 
(qPCR) of SP-A and SP-D mRNA levels. Exposure to ethanol during pregnancy 
significantly blocked stimulated increase in CBF though ethanol-mediated 
desensitization of cAMP–dependant protein kinase (PKA). In addition, 
prematurely-born/ethanol-exposed lambs showed significantly decreased SP-A 
m-RNA expression when compared to the prematurely born/control group (p=0.004); 
no significant changes were seen with SP-D. The full-term/ethanol exposed lambs 
had no significant alterations in mRNA levels, but had significantly less detectable 
SP-A protein when compared to the full-term/control lambs (p=0.02). These findings 
suggest that chronic maternal ethanol consumption during the third trimester of 
pregnancy alters innate immune gene expression in fetal lung. These alterations 
may underlie increased susceptibility of premature infants exposed to ethanol in 
utero to RSV and other microbial agents. 
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1. Introduction 
The innate immune response of lung epithelia represents the first line of 
defense against potentially pathogenic microorganisms present in inspired air. 
These responses can immediately prevent colonization and proliferation of 
microbes, thus minimizing the involvement of the adaptive immune response and 
allowing efficient gaseous exchange. The respiratory tract innate immune system 
prevents initial colonization of airborne microorganisms through at least three distinct 
mechanisms. First, microorganisms trapped in the respiratory mucus can be 
removed mechanically by mucociliary activity. Second, when invading microbes 
reach the deeper respiratory compartments, such as the alveolar lumen, cellular and 
secretory mechanisms are triggered. These include alveolar macrophages, 
intravascular macrophages, and other cells with phagocytic and pro-inflammatory 
properties such as eosinophils (Aderem and Underhill 1999; Underhill and Ozinsky 
2002). The third mechanism involves antimicrobial peptides, proteins and other 
molecules secreted by respiratory epithelia (Brogden, Ackermann et al. 2003; Bals 
and Hiemstra 2004; Hiemstra and Bals 2004). Ethanol exposure significantly alters 
at least some of these lung innate responses (Happel and Nelson 2005) in adults. 
While each of these innate immunity mechanisms are important in the initial 
respiratory host defense, their activity in individuals born pre-term with or without the 
influence of intrauterine ethanol exposure is poorly understood.   
Alveolar type II cells (ATII) as well as non-ciliated bronchial and bronchiolar 
epithelial cells (Clara cells) secrete lung surfactant. Surfactant is a mixture of 
phospholipids which primarily functions to prevent alveolar collapse during 
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end-expiration (Ochs 2006). However, in addition to this physiological function, 
surfactant has been found to have potent antimicrobial properties which are largely 
attributed to the hydrophilic, collectin-like surfactant protein A and D (Crouch, 
Hartshorn et al. 2000; LeVine and Whitsett 2001; Sano and Kuroki 2005; Grubor, 
Meyerholz et al. 2006; Kingma and Whitsett 2006; Kishore, Greenhough et al. 2006). 
The secretion of SP-A and SP-D is regulated by developmental stage (King, Ruch et 
al. 1975; Mescher, Platzker et al. 1975; Kawashima, Meyerholz et al. 2006), 
hormones and potentially, by environmental factors such as alcohol consumption. 
Infants born prematurely exhibit increased susceptibility to and severity of 
infections with RSV (Rossi, Medici et al. 2007). Risk factors associated with 
premature birth include maternal alcohol consumption, smoking, drug abuse and 
poor nutrition (Hack, Flannery et al. 2002; Parazzini, Chatenoud et al. 2003; 
Albertsen, Andersen et al. 2004; Kyrklund-Blomberg, Granath et al. 2005). Alcohol 
consumption during pregnancy has been associated with many harmful effects in the 
developing fetus. Most studies have focused on neurodevelopmental (Riley and 
McGee 2005; West and Blake 2005) and behavioral anomalies (Mattson, 
Schoenfeld et al. 2001; Sood, Delaney-Black et al. 2001) in infants born from 
mothers who drank during pregnancy. Recently it has been suggested that in 
addition to neurodevelopmental effects, ethanol may play a significant role in 
immunomodulation and consequential increase in susceptibility to various infectious 
in newborn infants (Gauthier, Manar et al. 2004; Gauthier, Drews-Botsch et al. 2005; 
Gauthier, Ping et al. 2005). It is our hypothesis that ethanol consumption during 
pregnancy alters mucociliary clearance and expression of SP-A and/or SP-D by fetal 
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lung epithelia. Moreover, we suspect that intrauterine fetal ethanol exposure may 
more severely affect those born prematurely than those born full-term since full-term 
infants have had additional time to allow for lung epithelial cell maturation. To do this 
we have developed an ovine model. Gestating ewes and their offspring are 
well-suited for these studies since: 1) alveolar development in lambs occurs 
pre-natally as in humans unlike rodents; 2) lambs can be derived pre-term and 
survive unlike many other animal models (Meyerholz, Grubor et al. 2004); 3) ovine 
respiratory epithelia of airways, distal bronchioles and alveoli are similar to those of 
human lung and the ovine lung has submucosal glands not present in some animal 
models (Meyerholz, Grubor et al, 2004; Meyerholz, Kawashima et al, 2006); 4) 
expression of SP-A and SP-D and other innate immune genes of ovine lung are 
well-characterize and very similar to human (Grubor, Meyerholz et al, 2006; 
Meyerholz, Kawashima et al 2006); and 5) pre-term lambs are susceptible to RSV, a 
known pathogen of premature infants and maternal ethanol consumption is a risk for 
pre-term birth (Meyerholz, Grubor et al, 2004). Finally, sheep have long been used 
for respiratory studies related to human disease as well as the effects of ethanol on 
fetal brain development (Mescher, Platzker et al, 1975). 
2. Materials and Methods 
2.1. Experimental design:  
Animal use and experimental procedures were approved by Iowa State 
University’s Animal Care and Use Committee according to the requirements of the 
NIH guide for the Care and Use of Laboratory Animals. Abomasal cannula was 
surgically implanted in 16 mixed breed (1/2 Rambouillet, 1/4 Dorset, and 1/4 
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Finsheep), date-mated, pregnant ewes approximately 6 weeks prior to lambing 
dates. The ewes were randomly assigned to two groups, an ethanol-exposed and a 
control group. Within these groups, ewes were further randomly assigned to a 
full-term group in which the lambs were naturally delivered and a pre-term group in 
which the lambs were delivered prematurely via abdominal incision and uterotomy 
(day 138 of gestation, term=147). The ewes received either ethanol or water five 
days a week for three weeks. A total of twenty four lambs were obtained and 
assigned to experimental groups. Each group had 6 lambs (n=6 lambs).  
2.2 Abomasal cannulation: 
The delivery of ethanol into the ovine abomasum allows bypass of the rumen 
and degradation by ruminal microflora. It also promotes hepatic bio-metabolism as 
the abomasum is the “true” stomach of ruminants and empties directly into 
duodenum. Pregnant ewes were deprived of water and food for 12 hr prior to 
induction of anesthesia. Anesthesia was induced by administration of Telazol (1-2 
mg/kg, I.M; Fort Dodge, IA) and ewes were positioned in the dorsal recumbence. 
General anesthesia was maintained by inhalation of 2% isoflurane. The median 
abdominal and right paracostal regions were prepared for aseptic surgery. The 
initial, 10 cm incision was made from umbilicus to the epigastric region. Abomasum 
was identified, exteriorized, and isolated by towels moistened with sterile saline. A 
½” polyethylene cannula (Bar Diamond, Parma, ID) was placed in the pyloric antrum 
and the abomasal incision was closed with purse string sutures. A second 5 cm long 
incision was made in the right paracostal region and the cannula shaft was 
exteriorized. To secure the cannula placement, an additional 4 sutures through the 
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cannula ring were added. Finally, both abdominal incisions were sutured closed 
(Figure 1).  
2.3 Ethanol administration protocol:  
In 16 pregnant ewes, 40% ethanol at 1gr/kg, V/V (Sigma, St. Louis, MO) 
administration began 5 days after cannula insertion and was repeated 5 days a 
week during the last 5 weeks of gestation. Control ewes received the equivalent 
amount of water. After 4 weeks of ethanol administration (5 days/week) serum 
alcohol (ethanol) concentrations (SAC) were determined at 6, 12 and 24 hours post 
a single infusion by headspace gas chromatography analysis (University of Iowa 
Diagnostic Laboratories, Iowa City, IA)  
2.4 Tissue collection:  
Within 24 hr of natural lambing or uterotomy, all lambs were euthanized by 
intravenous administration of sodium pentobarbital and lung tissue was collected 
immediately. The samples from the left and right cranial lobes were collected into 
cryovials, snap frozen in liquid nitrogen and stored at -80°C until RNA extraction and 
qPCR analysis. The remaining tissue from the same lung lobes were fixed in 10% 
buffered formalin for IHC. The tracheas were collected into complete Dulbecco’s 
modified Eagle’s medium (complete DMEM), placed on ice and immediately shipped 
for mucociliary activity analysis (Department of Internal Medicine, University of 
Nebraska Medical Center, Pulmonary and Critical Care Medicine Section).  
2.5 Ciliary Beat Frequency analysis:  
A total of 6 lamb tracheae were obtained, 3 from full-term control lambs (n=3 
lambs) and 3 from full-term alcohol exposed lambs (n=3 lambs). Lamb tracheae 
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were sliced into 2-5 mm rings and placed in M199 media in 35 mm tissue culture 
dishes (Falcon, Franklin Lakes, NJ). Tissues were maintained at room temperature 
(25°C ± 0.5°C) during assay procedures using a thermostatically-controlled heated 
stage. Cilia motion frequency was quantitated using the Sisson-Ammons Video 
Analysis (SAVA) system. Images of ciliated cells were visualized by inverted phase-
contrast microscope, digital video images captured and analyzed for motion by 
SAVA using a process known as Whole Field Analysis (Sisson, Stoner et al. 2003). 
The SAVA software analyzed each image containing 19,200 possible motile zones 
to determine the average frequency and the standard error of the mean for each 
field captured. For each experimental condition, a minimum of 6 separate fields were 
captured, analyzed and expressed as a data point.  
2.6 Determination of cAMP-dependent Kinase Activity:  
PKA activity was determined in crude whole-cell fractions of tracheal epithelial 
cells. Tracheae were exposed to M199 (media control) or 100 µM isoprotrenol for 1 
hour and the tracheal epithelial cells were scraped from the luminal surface of the 
tracheae using a sterile cell lifter. Cells were flash frozen on liquid nitrogen in a cell 
lysis buffer consisting of phosphate buffered saline (pH 7.4) containing protease 
inhibitors (1 g/ml each of leupeptin, aprotinin, PMSF and chymostatin). Cell lysates 
were sonicated and particulates removed by centrifugation. Protein concentration 
was determined by the Bradford method (Schleicher and Wieland 1978) with 
Bio-Rad protein reagent (Bio-Rad, Hercules, CA).This PKA assay has been 
previously described in detail (Wyatt and Sisson 2001). Kinase activity was 
expressed in relation to total cellular protein assayed and expressed in terms of 
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picomoles of phosphate incorporated/min/mg of total protein assayed. All samples 
were assessed in triplicate and no less than three separate experiments were 
performed per unique parameter.  
2.7 qPCR analysis:  
Our approach to this procedure has been previously described in detail 
(Gallup and Ackermann 2006; Kawashima, Meyerholz et al. 2006). Briefly, total RNA 
was isolated from whole lung tissue samples and assessed for quantity and purity by 
spectrophotometry. This procedure was followed by DNase treatment (TURBO 
DNA-free kit, Ambion, Austin, TX). Prior to qPCR analysis, a test plate was run to 
determine which RNA dilution ranges gave the best signal (lacked inhibition and 
exhibited LOG-linear behavior and amplification efficiencies >80%) for SP-A and 
SP-D targets. The DNase treated RNA isolates were diluted 1:10 with nuclease-free 
water, then diluted to their ideal ranges on a per-sample, per-target basis (according 
to what was learned from the test plate analysis), and further placed in duplicate into 
96-well qPCR reaction plates (Applied Biosystems Incorporated, Forest City, CA). 
Each initially-prepared 30 μl reaction contained 7.8 μl of DNase treated, 
appropriately-diluted RNA isolate, 15 μl of a commercially available Applied 
Biosystems One-Step Master Mix, 1000 nM primers, 150 nM TaqMan (5’-6FAM, 
3’-TAMRA-quenched) probe, and nuclease-free water. The negative, no-template 
control wells contained nuclease-free water (Ambion) instead of RNA isolate. 27 μl 
of each reaction was used in-well in the 96-well reaction plates. The plates were run 
in the GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster 
City, CA) for detection and relative quantification of SP-A and SP-D mRNA targets. 
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The results were analyzed by using the GeneAmp 5700 software and departmentally 
available Excel files. In addition, the real-time mRNA data are normalized to S15 
mRNA.  
2.8 IHC analysis:  
This procedure and scoring system has been previously described in detail by 
our laboratory (Grubor, Gallup et al. 2004). Briefly, sections of lung on glass slides 
were deparaffinized and rehydrated followed by antigen retrieval, a protein blocking 
procedure, SP-A specific primary antibody incubation (Mouse IgM anti-human SP-A 
antibody, Chemicon International, Inc., Temecula, CA), secondary antibody 
application (biotinylated Rat anti-Mouse Isotype Rat (LOU) IgG2a,, B.D. 
Pharmingen, San Diego, CA), streptavidin-conjugated horseradish peroxidase 
incubation (BioGenex, San Ramon, CA) and Nova Red substrate (Vector, 
Burlingame, CA) development. All slides were counter-stained with Shandon’s 
¼-strength hematoxylin (Shandon-Lipshaw, Pittsburgh, PA), dehydrated through a 
series of graded solvents, and cover-slipped using Permount (Fisher, Hanover, IL) 
according to standard IHC protocol. For IHC scoring system, five fields of each lung 
section were assessed for intensity and distribution of SP-A stained epithelial cells in 
the terminal bronchioles and bronchiolar/alveolar junctions. Scoring was based on 
predetermined scale; 0, no staining of cells; 1, <30% of epithelial cells stained with 
minimal detectable intracytoplasmic staining; 2, 30-60% of epithelial cells stained 
with minimal detectable intracytoplasmic staining; 3, 30-60% of epithelial cells 
stained with >50% of cytoplasm stained; 4, >60% of epithelial cells stained with 
>50% of cytoplasm stained.  
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2.9. Statistical analysis: 
For CBF data, ANOVA was run on each data point. For determination of 
cAMP-dependent Kinase Activity data was analyzed for statistical significance using 
one-way ANOVA. For IHC and qPCR data, summary statistics (mean and standard 
error of the mean) were calculated for each experimental group. Student-t tests 
(Graph Pad Sigma software, San Diego, CA) were also performed on normalized 
qPCR and IHC-score data. The acceptable level of significance was p<.05 
3. Results  
3.1 Sheep serum alcohol (ethanol) concentration   
The ethanol in the maternal serum was measured 6 hr post-infusion and 
ranged from undetectable (in one ewe) and 10-32 mg/dl (in other 7ewes), mean 
was16.3 +/- 4.36 mg/dL. Ethanol was undetectable at 12 and 24 hours in these ewes 
(Table 1).  
3.2 CBF results: 
Ex vivo tracheal CBF was assayed in full-term lambs delivered to both control 
and ethanol-exposed pregnant ewes. In ethanol-exposed trachea, baseline CBF did 
not significantly differ from control trachea (Figure 2A). However, 
isoproterenol-stimulated CBF increases in control lamb tracheal rings were not 
observed in tracheal rings obtained from ethanol-exposed lambs. Because 
isoproterenol-stimulated CBF increases require the activation of PKA (Wyatt, 
Spurzem et al. 1998) epithelial cell PKA activity was also assayed in this study. 
Isoproterenol significantly increased PKA activity in control trachea, but failed to 
activate PKA in ethanol-exposed trachea (Figure 2B). 
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3.3 qPCR results:  
Pregnant ewes that received ethanol during the last 5 weeks of gestation 
showed significantly reduced SP-A mRNA expression in lungs of lambs delivered 
prematurely (p=0.004) compared to pre-term/control lambs not receiving ethanol 
(Figure 3). Although maternal ethanol administration exhibited a tendency toward 
decreased SP-D mRNA expression in pre-term lambs when compared to pre-
term/control lambs, this difference was not statistically significant (p=0.4, Figure 4). 
In full-term lambs, there was no significant change in both SP-A and SP-D mRNA 
expression between full-term control and full-term/ethanol exposed lambs.  
3.4 IHC analysis results:  
SP-A antigen was detected within the cytoplasm of terminal bronchiolar and 
bronchiolar/alveolar junction epithelial cells in all four groups of lambs. The mean 
score for all for groups was; PTC, 1.7 +/- 0.15; FTC, 2.88 +/-0.39; FTA, 1.66 +/-0.38 
and PTA, 2.00 +/-0.41. The pre-term/control group (Figure 5D) had significantly less 
detectible SP-A-specific staining when compared to the full-term/control group 
(p=0.02, Figure 5B). The full-term/alcohol exposed group (Figure 5A) had 
significantly less detectible SP-A-specific staining (reduced SP-A protein expression) 
when compared to the full-term/control group (p=0.04, Figure 5B).  
4. Discussion  
The finding that maternal ethanol exposure reduces the expression of SP-A 
and CBF in fetal lung demonstrates that ethanol has transplacental effects on key 
aspects of lung innate immunity. The decreased expression of SP-A mRNA in lungs 
of lambs born prematurely and exposed to ethanol in utero when compared to 
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prematurely born, control lambs lacking in utero ethanol exposure suggests that 
ethanol may even further hinder innate immunity beyond the level of a normal pre-
term individual. Our previous studies have shown that innate immune gene 
expression in pre-term lambs is significantly reduced compared to full-term lambs 
(Hallman, Glumoff et al. 2001; Kawashima, Meyerholz et al. 2006) and ethanol may 
exacerbate this alteration. In this study, pre-term/control (without ethanol exposure) 
SP-A mRNA levels tended to be reduced in comparison to full-term lambs. However, 
this reduction was not significant (p=0.9). This was expected since the gap in age 
between pre- and full-term lambs in this current study is less (9 days) than in our 
previous studies (17-32 days) (Meyerholz, Kawashima et al. 2006). 
Although SP-A mRNA levels were reduced in the lungs of pre-term lambs 
exposed to ethanol in utero, SP-A protein expression was not significantly altered. 
We suspect that this might be explained by decreased secretion of SP-A protein by 
the immature lung epithelial cells (Hallman, Glumoff et al. 2001). It is possible that 
ethanol may suppress SP-A transcriptional activity in immature epithelia and SP-A 
protein release into the airway. Both of these alterations by ethanol may greatly 
affect innate defense.   
In contrast to pre-term lambs, SP-A mRNA levels were not altered in full-term 
lambs with or without ethanol exposure in utero. We suspect that the additional 
gestation time may allow the lung epithelia to further mature and reach a critical 
point for essential SP-A transcription. The reduced SP-A protein detected in lungs of 
full-term/ethanol exposed lambs compared to the full-term/control lambs may 
suggest that while a mature level of SP-A gene transcription may occur at this 
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developmental stage, there may be a time of “catch up” needed in newborn lambs to 
release mature protein into the airway lumen. Alternatively, ethanol may have a 
residual effect on post-translational intracellular mechanisms. Both of these findings 
suggest that ethanol has a suppressive effect on SP-A depending on the 
developmental stage of the animal. Age-specific mechanisms are likely different as 
well.  
The decrease in stimulated trachea CBF in lambs exposed to ethanol is 
consistent with previous studies. Ethanol can have a detrimental effect on this lung 
protective mechanism depending on the length of exposure. When acutely-exposed 
to ethanol, the ciliary beat frequency in bovine bronchial epithelial cells was 
increased (Wyatt, Forget et al. 2003). Interestingly, when chronically exposed to 
ethanol, the effect was quite opposite and ciliary beating was decreased (Wyatt and 
Sisson 2001). This chronic desensitization of cilia stimulation by ethanol has also 
been demonstrated in vivo in rat (Wyatt, Gentry-Nielsen et al. 2004) and mouse 
(Elliott, Sisson et al. 2006) models. Unique to our current study is the observation 
that maternal transmission of ethanol-mediated desensitization occurs in the full-
term lamb as well. The combination of reduced SP-AD expression and decreased 
clearance due to desensitized CBF may underlie the increased susceptibility of the 
pre-term lung (exposed to maternal alcohol consumption) to infectious agents such 
as RSV.  
The CBF and SP-A findings in fetal lung are consistent with studies that show 
an overall immunosuppressive effect of ethanol. For example, chronic alcoholics 
have an increased incidence and higher mortality rate related to bacterial pneumonia 
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(Jong, Hsiue et al. 1995; el-Ebiary, Sarmiento et al. 1997; de Roux, Cavalcanti et al. 
2006) and a three-fold increase in incidence of infection and sepsis after surgery 
(von Dossow, Schilling et al. 2004). In HIV patients, concurrent alcohol consumption 
increases the susceptibility to various infections (Justice, Lasky et al. 2006). 
Maternal alcohol consumption during pregnancy and its effects on fetal immunity 
remains a largely unexplored area of clinical significance. Several studies have 
already demonstrated that newborns exposed to ethanol during prenatal life have a 
higher incidence of infection (Gauthier, Manar et al. 2004; Gauthier, Ping et al. 
2005). The exact mechanism by which this occurs is not fully understood but it is 
possible that reduction in tracheal CBF and SP-A may increase susceptibility to 
infections. Ethanol consumption has been shown to have a suppressive effect on 
cellular components of the innate immune system such as macrophages (Gauthier, 
Ping et al. 2005) and/or neutrophils (Vinson, Carroll et al. 1998), all of which may 
occur concurrently with reductions in CBF and SP-A. 
Although lung epithelia secrete many antimicrobial peptides, proteins and 
molecules, SP-A and SP-D are among the most extensively-studied pulmonary host 
defense/innate proteins. They are constitutively expressed and secreted by alveolar 
type II cells and Clara cells (Crouch, Parghi et al. 1992) and belong to a subgroup of 
collectin-containing mammalian C-type lectins, called collectins (Kishore, 
Greenhough et al. 2006). SP-A and SP-D can bind, aggregate and opsonize many 
microorganisms including Gram-negative and Gram-positive bacteria, enveloped 
viruses like Influenza A Virus (IAV), RSV, non-enveloped viruses like Rotavirus and 
fungal organisms in order to protect lung from possible infection (Grubor, Meyerholz 
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et al. 2006). In animal studies, the deficiency of SP-A, SP-D or both were associated 
with increased susceptibility to pulmonary Pseudomonas aeruginosa (LeVine, Kurak 
et al. 1998) and Streptococcal infections(LeVine, Bruno et al. 1997). Also, elevated 
levels of SP-AD mRNA in the lungs of neonatal lambs are associated with clearance 
of Parainfluenza virus-3 (PIV-3) (Grubor, Gallup et al. 2004). Another study showed 
that SP-AD enhance mannose receptor mediated phagocytosis of Mycobacterium 
avium by macrophages (Kudo, Sano et al. 2004). Also, the reduced clearance of 
RSV in lambs is associated with prematurely and possibly inadequate expression in 
pulmonary collectins (Meyerholz, Grubor et al. 2004) while SP-A enhances RSV 
clearance in mice (LeVine, Gwozdz et al. 1999).  
In addition, when SP-A,D are administered to the lung in the murine model of 
invasive pulmonary aspergillosis, the mortality rate of infected animals was 
significantly reduced (Kishor, Madan et al. 2002). In rats, administration of SP-A 
reduces the oxidative damage of ventilated lungs (Bailey, Maruscak et al. 2006). In 
ventilated lambs, SP-A did not reduce inflammation indicators caused by 
inflammation (Ikegami and Jobe 2002). However, there were no negative effects 
associated with SP-A administration.  
In this study, we have shown that a moderate level of alcohol consumption 
during the third trimester of pregnancy significantly decreases the levels of SP-A 
gene expression in prematurely born lambs while SP-D remained unaffected. The 
exact mechanism of this alcohol-related immunosuppressive effect is not clear but 
we suspect that ethanol may have a direct effect on lung epithelial cells, particularly 
ATII cells and/or Clara cells. For example, Brown et al. have previously shown that 
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chronic ethanol ingestion potentiates apoptosis of ATII cells in rats (Brown, Harris et 
al. 2001). The results of this experiment suggest that chronic ethanol exposure 
decreases the bioavailability of glutathione (GSH) to mitochondria of ATII cells. As a 
consequence, ATII repair mechanisms are diminished – resulting in a significant 
decrease in numbers of these SP-A-producing cells. Also, the same investigators 
have previously published that chronic ethanol exposure and GSH depletion 
activates matrix metalloproteinases (MMP’s) which consequentially degrade lung 
epithelial cells (Lois, Brown et al. 1999). Although this might be a possible 
mechanism of ethanol-induced lung innate immunity impairment, other researchers 
have shown that prenatal exposure to ethanol effects maternal-fetal-hormonal 
interactions which in-turn substantially affects the functional immunity of offspring. 
Zhang at al. have demonstrated that alcohol consumption during pregnancy 
increases Hypothalamic-Pituitary-Adrenal (HPA) responsiveness in rat pups in such 
a way that ethanol-exposed neonates exhibit reduced increase responsiveness in 
early and pre-weaning life (Zhang, Sliwowska et al. 2005). The exact nature and 
significance of this disturbed hormonal homeostasis still needs to be determined but 
it is possible that insufficient neonatal corticosteroid levels might be an underlying 
indicator for inadequate lung surfactant production. In addition, moderate levels of 
ethanol consumption are related to an increased incidence of premature birth 
(Parazzini, Chatenoud et al. 2003; Albertsen, Andersen et al. 2004). As previously 
demonstrated in our lab, premature birth is significantly correlated to decreased 
expression of SP-AD (Meyerholz, Kawashima et al. 2006).  
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In developing this ovine model, a cannula was placed into the abomasum for 
ethanol delivery. This allowed us to bypass the rumen and access a part of the ovine 
gastrointestinal tract that more accurately mimics the stomach of humans. The 
abomasum is the "true" stomach of ruminants out of which there is unimpeded flow 
of abomasal contents into the duodenum and small intestine – similar to gastric 
contents emptying into the small intestine of humans. The delivery of ethanol into the 
ovine abomasums in this manner allows for its absorption and passage into the 
portal veins draining into the liver thereby promoting hepatic bio-metabolism (Lieber, 
Gentry et al. 1994), which is similar to the route of ethanol in humans.  
As indicated, the levels of ethanol used in this study were similar to those of 
moderate, not excessive alcohol consumers (Brien, Clarke et al. 1987).There is 
debate over "safe" levels of alcohol consumption during pregnancy, and many 
studies recommend complete abstinence from alcohol during gestation altogether 
(Martinez-Frias, Bermejo et al. 2004).  
In conclusion, moderate alcohol consumption during the last trimester of 
pregnancy in sheep is associated with significant reduction of SP-A and CBF in 
lambs born prematurely. The deficiency in surfactant proteins, including SP-A, is 
associated with increased susceptibility to neonatal infections including RSV 
(Griese, Maderlechner et al. 2002). This finding may have clinical significance and 
will allow us to further investigate RSV infection as a means to address the 
hypothesis that ethanol exposure during pregnancy may increase RSV susceptibility 
in human infants. 
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Tables  
 Ewe 1 Ewe 2 Ewe 3 Ewe 4 Ewe 5 Ewe 6 Ewe 7 
6hr 0 23 11 10 10 28 32 
12hr 0 0 0 0 0 0 0 
24hr 0 0 0 0 0 0 0 
 
Table 1. Serum alcohol concentrations in mg/dl, in acclimated (receiving daily 
ethanol for five days for three weeks) pregnant ewes at six, 12 and 24 hours after a 
single infusion (40% at 1 mg/kg, V/V). 
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Figures 
 
Figure 1. Intra-abomasal cannula for alcohol delivery. The canula is present along 
the ventral right paralumbar area. To deliver alcohol, the screw-cap is released and 
a catheter is inserted and alcohol enters by gravity flow. 
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Figure 2. Ewes were exposed to alcohol as described. 6 lambs were sacrificed and 
tracheal ring cilia were incubated with control media or 100 µM isoproterenol (ISO) 
for 30 min. CBF (panel A) and PKA (panel B) were assayed. ISO significantly 
stimulates increased lamb tracheal epithelial CBF and PKA from control ewes 
(*p<0.05; n=3 lambs). Maternal alcohol exposure desensitizes the lamb cilia to beta-
agonist stimulated increases in CBF and PKA (n=3 lambs). 
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Figure 3. The relative SP-A mRNA expression in pre-term control (PTC), and 
full-term control (FTC) lambs as well as pre-term alcohol-exposed (in utero) (PTA) 
and full-term alcohol-exposed (in utero) lambs (FTA). The FTC and PTC values are 
equal to one. The PTA and FTA values are presented relative to the corresponding 
controls. The SP-A mRNA expression is significantly reduced (p=0.004) in PTA 
lambs (n=6 lambs) when compared to PTC lambs (n=6lambs). There is no 
significant change in SP-A mRNA expression between FTA and FTC lambs. 
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Figure 4. The relative SP-D mRNA expression in pre-term and full-term lambs with 
or without (control) maternal alcohol administration during gestation. Although 
maternal alcohol administration had a tendency to decrease the SP-D mRNA 
expression in the pre-term/alcohol exposed lambs (PTS), (n=6 lambs) when 
compared to the pre-term/control lambs (PTC), (n=6 lambs), this difference was not 
statistically significant (p=0.4). There is no significant change in SP-D mRNA 
expression between full-term/alcohol exposed and full-term/control lambs. 
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Figure 5. Representative immunohistochemical detection of SP-A protein in 
bronchial/bronchiolar epithelium of the full-term/alcohol exposed lambs (A), full-term 
control lambs (B), pre-term/alcohol exposed lambs (C), and pre-term control lambs 
(D). High distribution and intensity of staining is seen in pre-term lambs receiving 
alcohol, suggesting that alcohol may affect SP-A protein release from epithelial cells. 
Arrows depict epithelial cells with SP-A protein expression.  
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CHAPTER 3. EFFECTS OF NICOTINE ON PULMONARY SURFACTANT 
PROTEINS A AND D IN OVINE LUNG EPITHELIA 
A paper accepted for publication in Pediatric Pulmonology 
Tatjana Lazic, DVM, MS,  Milan Matic, DVM,  Jack M. Gallup, MS,   
Albert Van Geelen, PhD,  David K. Meyerholz, DVM, PhD, Branka Grubor, DVM, 
PhD, Paula M. Imerman, PhD,  Marcia M. M. A. de-Macedo, PhD,   
and Mark R. Ackermann, DVM, PhD 
Summary 
Maternal smoking during pregnancy increases the incidence and severity of 
respiratory infections in neonates. Surfactant proteins A and D (SP-A and SP-D, 
respectively) are components of pulmonary innate immunity and have an important 
role in defense against inhaled pathogens. The purpose of this study was to 
determine if nicotine exposure during the third trimester of pregnancy alters the 
expression of SP-A and SP-D of fetal lung epithelia. Pregnant ewes were assigned 
to four groups; a nicotine-exposed full-term and pre-term group, and control full-term 
and pre-term group. Lung tissue was collected for Western blot and IHC analysis of 
SP-A level, Western blot analysis of SP-D level and qPCR analysis of SP-A and SP-
D mRNA expression. Exposure to nicotine significantly decreased SP-A gene 
expression (p=0.01) and SP-A protein level in pre-term lambs. This finding suggests 
that maternal nicotine exposure during the last trimester of pregnancy alters a key 
component of lung innate immunity in offspring. 
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1. Introduction    
The lungs are constantly exposed to potentially pathogenic microorganisms 
present in the inspired air. Microbial agents trigger responses of the innate immune 
system of lung epithelia which reduces microbial colonization and infection. In 
addition, an effective innate immune response by epithelia minimizes the adaptive 
immune responses, thereby reducing leukocytic infiltration and allowing efficient 
pulmonary function and gaseous exchange.  
The lung innate immune system includes three major components: physical 
barrier, cellular responses, and secretory products. The physical barrier includes 
respiratory tract epithelia and constant ciliary movement in order to propel invading 
particles out of the respiratory tract1. The alveolar macrophages, intravascular 
macrophages, and other cells with phagocytic and pro-inflammatory properties are 
cellular components which function to prevent pulmonary infection2. The secretory 
component includes antimicrobial peptides, proteins, and other molecules secreted 
by respiratory epithelia which line the pulmonary airways3. Surfactant proteins A and 
SP-D are key elements of the secretory lung innate immune defense. They are 
synthesized and secreted by alveolar type II cells (ATII) and non-ciliated bronchial 
and bronchiolar epithelial cells (Clara cells)4. Surfactant protein A and SP-D are 
involved in host defense against various bacterial and viral pathogens. The secretion 
of SP-A and SP-D is regulated by developmental stage5, hormones and, potentially, 
by environmental factors such as cigarette smoke. 
Previous studies have shown that maternal smoking during pregnancy is 
associated with many adverse health effects in the developing fetus which may be 
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manifested during postnatal life6. Undoubtedly, maternal smoking during pregnancy 
is a major cause of premature birth7 and low birth weight for gestational age8. There 
is a relatively more recent body of work, suggesting that cigarette smoke is 
immunosuppressive and predisposes infants to respiratory infections6. Although 
cigarette smoke contains thousands of different chemicals, it is suspected that 
nicotine is a major immunomodulatory component since it readily crosses the 
placenta and accumulates in the fetal compartment9.            
It is our hypothesis that in addition to premature birth, cigarette smoking 
during pregnancy may have a significant regulatory role on lung surfactant protein 
and consequential increase in susceptibility to various respiratory infections in 
newborn infants. 
2. Materials and Methods 
2.1. Experimental design: 
Animal use and experimental procedures were approved by Iowa State 
University’s Animal Care and Use Committee according to the requirements of the 
NIH guide for the Care and Use of Laboratory Animals. The lateral neck region was 
clipped and fitted with a transdermal nicotine patch (21 mg, Nicoderm CQ, 
GlaxoSmithKline, Brentford, Middlesex, U.K) in 16 mixed breed (1/2 Rambouillet, 1/4 
Dorset and1/4 Finnish sheep), date-mated, pregnant ewes approximately 6 weeks 
prior to lambing dates. The ewes were randomly assigned to two groups, nicotine 
exposed group and a control group. Within these groups, ewes were further 
randomly assigned to a full-term group in which the lambs were naturally delivered 
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and a pre-term group in which the lambs were delivered prematurely via abdominal 
incision and uterotomy (day 138 of gestation, term=147). Prior to uterotomy, the 
ewes were anesthetized with tiletamine and zolazepam (Telazol, 1–2 mg/kg, I.M; 
Fort Dodge, IA) and upon uterotomy; the ewes were euthanized by administration of 
sodium pentobarbital (Beuthanasia-D, 2 ml/ 10 pounds, Schering-Plough Animal 
Health Corp., Union, NJ). The ewes received either nicotine or supportive bandage 
alone. A total of twenty four lambs were obtained and assigned to experimental 
groups. Full-term control (FTC) and pre-term control (PTC) groups had 6 lambs each 
(n=6), full-term nicotine exposed group (FTN) had 5 lambs (n=5) and pre-term 
nicotine exposed group (PTN) had 7 lambs (n=7). 
2.2. Nicotine administration protocol: 
Approximately 20 cm2 of the lateral neck region was shaved and cleaned. 
After the neck was dry, a 21 mg nicotine patch was placed on the skin and gentle 
pressure was applied over the patch for 5 minutes. The patch was secured by 
additional bandaging. Blood samples (10 ml) were drawn from the jugular vein 6, 12, 
and 24hr after patch placement and assessed for cotinine plasma levels (CPL) by 
HPLC analysis. The procedure was repeated on a daily basis during the last six 
weeks of pregnancy. 
2.3. Tissue collection: 
Lung tissue was collected within 24 hours of natural lambing or uterotomy. 
The samples from the most lateral portions of the right cranial lobes were collected 
into cryovials, snap frozen in liquid nitrogen, and stored at -80°C until protein and 
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RNA extraction for Western blot and qPCR analysis. The remaining tissue from the 
same lung lobes were fixed in 10% buffered formalin for immunohistochemistry 
(IHC).  
2.4. qPCR analysis: 
Methodology for qPCR analysis of SP-A and SP-D mRNA levels has been 
described previously in detail10,11. Briefly, total RNA was isolated from the fresh, 
frozen lung tissue and assessed for quantity and purity by spectrophotometry. This 
procedure was followed by DNase treatment (TURBO DNA-free kit, Ambion, Austin, 
TX). Prior to qPCR analysis, a test plate was run to determine which RNA dilution 
ranges gave the best signal for SP-A and SP-D targets. The DNase treated RNA 
isolates were diluted 1:10 with nuclease-free water, then diluted to their ideal ranges 
on a per-sample, per-target basis, and further placed in equal amount, in duplicate 
into 96-well qPCR reaction plates (Applied Biosystems Incorporated, Forest City, 
CA). The plates were run in the GeneAmp 5700 Sequence Detection System 
(Applied Biosystems, Foster City, CA) for detection and relative quantification of 
SP-A and SP-D mRNA targets. Results were gathered by the GeneAmp 5700 SDS 
software and processed using custom Excel files. In addition, the real-time mRNA 
data was normalized to ovine ribosomal protein S15 mRNA. 
2.5. IHC analysis: 
Surfactant protein A immunohistochemical staining have been described 
previously in detail by our laboratory12. Briefly, upon collection, the lung tissue was 
fixed in 10% buffered formalin for 24 hours. Prior to IHC run, 3 um thick tissue 
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sections were placed on glass slides. The glass slides were deparaffinized and 
rehydrated followed by antigen retrieval, a protein blocking procedure, SP-A specific 
primary antibody incubation (Mouse IgM anti-human SP-A, Chemicon International, 
Inc., Temecula, CA), secondary antibody application (biotinylated Rat anti-Mouse 
Isotype Rat (LOU) IgG2a, B.D. Pharmingen, San Diego, CA), 
streptavidin-conjugated horseradish peroxidase incubation (BioGenex, San Ramon, 
CA) and Nova Red substrate (Vector, Burlingame, CA) development. All slides were 
counter-stained with Shandon’s ¼-strength hematoxylin (Shandon-Lipshaw, 
Pittsburgh, PA), dehydrated through a series of graded solvents, and cover-slipped 
using Permount (Fisher, Hanover, IL) according to standard IHC procedure. For IHC 
scoring, five fields of each lung section were assessed for intensity and distribution 
of SP-A-stained epithelial cells in the terminal bronchioles and bronchiolar/alveolar 
junctions. Scoring was based on a predetermined scale; 0 = no staining of cells; 1 = 
<30% of epithelial cells stained with minimal detectable intracytoplasmic staining; 2 
= 30-60% of epithelial cells stained with minimal detectable intracytoplasmic 
staining; 3 = 30-60% of epithelial cells stained with >50% of cytoplasm stained; 4 = 
>60% of epithelial cells stained with >50% of cytoplasm stained.  
2.6. Western blot analysis: 
Fresh, frozen lung tissues (0.1 gram) collected from the lateral portion of the 
right, cranial lung lobe were homogenized in 2 ml T-PER® Tissue Protein Extraction 
Reagent (Pierce, Rockford, IL) containing Complete TM Protease Inhibitor Cocktail 
(Santa Cruz Biotechnology, Santa Cruz, CA). The tissue homogenates were 
centrifuged at 13,000 x RPM for 5 minutes at 4oC and supernatant (protein extract) 
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was collected. The sodium dodecyl sulfate (SDS) sample buffer was added and 
samples were boiled for 5 minutes. The protein extracts were loaded onto 
polyacrylamide gel (PAG, 8-16%, Precise TM Protein gels, Thermo scientific, 
Rockford, IL) for protein separation and then transferred to polyvinylidene fluoride 
transfer membrane (PVDF transfer membrane, Millipore, Bedford, MA). The 
membrane was blocked with 5% nonfat dry milk in 1X TBS, after which the 
membrane was incubated overnight at 4oC with the primary polyclonal rabbit anti 
bovine SP-A antibodies (Chemicon International, Inc, Temecula, CA) or primary 
polyclonal rabbit anti human SP-D antibodies (Santa Cruz Biotechnology, Santa 
Cruz, CA). Both antibodies were diluted in 1XTBS, 0.05% Tween and 5% nonfat dry 
milk at 1:1000. After rinsing 3 times for 5 minutes with 1XTBS, 0.05% Tween the 
membranes were further incubated for 90 minutes at room temperature with 
secondary Alexa Fluor 488 goat anti rabbit normal IgG antibodies (Invitrogen, 
Carlsbad, CA) diluted in 1XTBS, 0.05% Tween at 1:2000. To demonstrate equal 
loading of samples, a duplicate membrane was probed with monoclonal mouse anti 
β-actin antibodies (Sigma, St. Louis, MO) diluted in 1XTBS, 0.05% Tween at 1:5000 
and secondary antibody goat anti mouse Alexa fluor 488 at 1:2000. The 
fluorescence was detected by Typhoon imaging system (GE Healthcare, Baie d'Urfe, 
Quebec, Canada) using excitation wavelength 488 and 520 BP 40 emission filter. 
2.7. Statistical analysis: 
For qPCR and IHC data, summary statistics (mean and standard error of the 
mean) were calculated for each experimental group. Student’s-t tests (Graph Pad 
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Sigma software, San Diego, CA) were also performed on normalized qPCR and IHC 
data. The acceptable level of significance was p<0.05. 
3. Results 
3.1. Sheep cotinine plasma levels (CPL): 
The cotinine in the maternal plasma was measured 6, 12, and 24 hr after 
patch placement. 6 hr after patch placement, CPL ranged from 30 to 79 ug/ml with a 
mean of 49.8+/-6.7 ug/ml. 12 hr after patch placement, CPL ranged from 
undetectable (in 1 ewe) to 73 ug/ml with a mean of 45.4+/-7.22 ug/ml. 24 hr after 
patch placement, CPL ranged from undetectable (in 1 ewe) to 38 ug/ml with a mean 
of 30.0+/-2.59 ug/ml (Table 1).  
3.2. qPCR results: 
Pregnant ewes exposed to nicotine during the last six weeks of gestation had 
significantly reduced (p=0.01) SP-A mRNA expression in lungs of lambs to PTC 
lambs not exposed to nicotine. Although maternal exposure to nicotine exhibited a 
tendency toward decreased SP-D mRNA expression in PTN lambs when compared 
to PTC lambs, this difference was not statistically significant (p=0.09). The results 
are presented in Figure 1. There were no significant changes in both SP-A and SP-D 
mRNA expression between FTC and FTN lambs. 
3.3. IHC analysis results: 
The SP-A antigen was detected within the cytoplasm of terminal bronchiolar 
and bronchiolar/alveolar junction epithelial cells in all four groups of lambs (Figure 
2). This cellular localization of SP-A is similar to previous studies12. The mean score 
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for each group was: PTC, 1.9 +/- 0.15; FTC, 2.88 +/-0.39; PTN, 2.09+/-0.21 and 
FTN, 3.32+/-0.15. There was no statistical significance between FTC and FTN 
groups (p=0.1) as well as PTC and PTN (p=0.08) groups.  
3.4. Western blot results: 
The Western blot analysis detected a single ~35 kD band that corresponds to 
the expected size of SP-A protein and ~43 kD band that corresponds to the 
expected size of SP-D protein. The SP-A and SP-D proteins were detected in all four 
groups of lambs; PTC and PTN, FTC and FTN lambs. The SP-A bands were 
significantly less detectable in the PTN group when compared to PTC group (Fig. 3). 
This indicates decreased SP-A protein level in nicotine exposed, pre-term lambs 
when compared to the control group. The SP-A bands were similar in size in FTN 
group when compared with FTC group (Fig. 3). There was no difference in size of 
SP-D bands in PTN group when compared to PTC group or FTN group when 
compared to FTC group (Fig. 4).  
4. Discussion 
We found that maternal nicotine exposure during pregnancy significantly 
reduces SP-A gene expression and protein level in pre-term born lambs, while it has 
no significant effect in naturally delivered, full-term lambs. It is likely that the 
additional gestational time allows more complete transcriptional activation or 
enhanced cellular differentiation and proliferation of SP-A producing cells in full-term 
lambs. Nicotine exposure did not alter SP-D gene expression and protein level in 
pre-term or full-term born lambs. The qPCR results show wide standard errors of 
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mean. This may be explained by the fact that sheep used in this experiment are 
outbred. Individual genetic variability in these animals tends to be wide in contrast to 
commonly used experimental animals such are mice and rats, which are inbred and 
have less genetic variation within the same strains. Although the wide errors of 
mean may question the validity of qPCR data, the protein levels determined by 
Western blot analysis closely parallel the qPCR findings which confirm biological 
significance of changes determined at mRNA levels. The IHC analysis did not show 
any statistically significant difference in SP-A protein level in PTN lambs when 
compared to PTC group; the significant difference was not present between FTN 
and FTC groups. This finding does not closely match the Western blot results in 
which the SP-A protein level was reduced in nicotine exposed lambs born 
prematurely compared to the controls. This may be explained by the fact that the 
IHC scoring system includes only proteins located within the intracellular 
compartment (intracytoplasmic SP-A) and does not take into account proteins 
located within the extracellular compartment (SP-A secreted into intra alveolar 
space). In contrast, Western blot analysis measures protein located in both 
intracellular and extracellular compartments and therefore represents a more 
sensitive and more reliable method of lung surfactant protein level determination.   
Surfactant proteins are considered to be the key aspect of secretory lung 
innate immunity, and nicotine-induced suppressive effects may explain, in part, the 
increased susceptibility of pre-term born, nicotine-exposed neonates to lower 
respiratory infections. Although lung epithelia secrete many antimicrobial peptides, 
proteins and molecules, SP-A and SP-D are among the most extensively studied 
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pulmonary host defense/innate proteins. They are constitutively expressed and 
secreted by ATII cells and Clara cells and belong to a subgroup of 
collectin-containing mammalian C-type lectins, called collectins13, SP-A and SP-D 
can bind, aggregate, and opsonize many microorganisms including Gram-negative 
and Gram-positive bacteria, enveloped viruses like Influenza A Virus (IAV), RSV, 
non-enveloped viruses like Rotavirus, and fungal organisms in order to protect lung 
from potential infection13. In animal studies, the deficiency of SP-A, SP-D, or both 
were associated with increased susceptibility to pulmonary Pseudomonas 
aeruginosa14 Streptococcal infections15. Elevated levels of SP-A and SP-D mRNA in 
the lungs of neonatal lambs are associated with clearance of Parainfluenza virus-3 
(PIV-3)13. Also, reduced clearance of RSV in lambs is associated with prematurity 
and inadequate expression of pulmonary collectins12, while SP-A has been shown to 
enhance RSV clearance in mice16. In addition, when SP-A and SP-D were 
administered to the lung in a murine model of invasive pulmonary aspergillosis, the 
mortality rate of infected animals was significantly reduced13. In rats, administration 
of SP-A reduces the oxidative damage of ventilated lungs17.  
Published data on the influence of smoking and nicotine on ATII cells, lung 
surfactant, and surfactant proteins are conflicting. There are several reports clearly 
indicating that cigarette smoking or nicotine alone affects alveolar ATII cells and, 
therefore, possibly lung surfactant metabolism. In a study published by Maritz and 
Thomas, intrauterine exposure of rat pups to nicotine resulted in increased 
proliferation of ATII cells18. Nicotine-exposed ATII cells exhibited obvious 
mitochondrial swelling and damage which may have disrupted adequate cellular 
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metabolism, including metabolism of lung surfactant and surfactant proteins. In the 
most recent study published by Rehan et al., nicotine exposure accelerated ATII cell 
proliferation, differentiation, and metabolism in rat embryonic lung and stimulated 
synthesis of surfactant lipids19. In both of these studies, however, the influence of 
nicotine on SP-A and SP-D was not investigated. A study conducted in healthy adult 
smokers showed reduced content of SP-A and SP-D in BAL fluid when compared to 
non-smokers20. A similar study conducted in rats confirmed this finding since rats 
chronically exposed to cigarette smoke had significantly reduced SP-A and SP-C 
levels in BAL fluid21. Several studies conducted in rats showed that maternal nicotine 
or cigarette smoke exposure alters the expression of surfactant proteins in neonatal 
pups. In one study, maternal nicotine exposure increased SP-A and SP-D 
expression in neonatal pups on postnatal day 7 and decreased SP-A and SP-D 
expression on postnatal day 1422. Yet, in another study conducted in rats, maternal 
side-stream cigarette smoke exposure showed reduced levels of SP-A in BAL of 
pups on postnatal day 1 and increased levels of SP-A in BAL on postnatal day 2123. 
There are reports, however, that suggest that maternal smoking does not influence 
lung surfactant proteins of exposed neonates. For example, neonates from mothers 
who smoked during pregnancy did not show reduced levels of SP-A according to 
amniotic fluid measurements24. There is also a report indicating that smoking in 
healthy individuals increases levels of SP-A when measured in serum25. In addition, 
there is scientific evidence that prenatal nicotine exposure has permanent 
detrimental effect on later postnatal lung development and function. It has been 
shown that in-utero exposure to nicotine influences the “programmed” lung aging 
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and maintenance thus accelerates aging and predisposes lung to parenchymal 
damage18.  
 In addition, there is controversy related to the safety of nicotine patch use 
during pregnancy. Although the nicotine patch is highly recommended as nicotine 
replacement therapy in pregnant women25 during the smoking cessation, to our 
knowledge there are no studies conducted to evaluate the effect of nicotine patch on 
developing fetus. In this study, we have shown that nicotine delivered to the mother 
by nicotine patch does have an undesirable effect on fetal lung epithelial 
development.  
Differences of the above studies with the lamb model are likely related to 
differences in animal lung maturation at the various stages of lung development, 
duration of nicotine or cigarette smoke exposure, as well as in the techniques used 
to determine surfactant protein levels. Although cigarette smoking during pregnancy 
remains a significant cause of neonatal mortality and morbidity, previous studies 
frequently utilized rodents as animal models which do not adequately parallel fetal 
lung development in humans. This is especially relevant in alveolar and pulmonary 
surfactant development research area. At birth, the lung of rodents is in saccular 
stage and alveoli with lung surfactant develop during first three weeks of post natal 
life26. In contrast, gestating ewes and their offspring are well-suited for these studies 
since: 1) alveolar development in lambs occurs prenatally as in humans26; 2) lambs 
can be derived pre-term and survive, unlike many other animal models12; 3) ovine 
respiratory epithelia of airways, distal bronchioles, and alveoli are similar to those of 
the human lung including similar numbers of Clara cells (which can reach 50% of the 
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epithelium of mice), and the ovine lung has submucosal glands not present in some 
animal models10,27; 4) expression of SP-A and SP-D and other innate immune genes 
of ovine lung are well-characterized and are very similar to human orthologs10; and 
5) pre-term lambs are susceptible to RSV, a known pathogen of premature infants, 
and maternal cigarette smoking is a risk for pre-term birth. Finally, sheep have long 
been used for respiratory studies related to human disease as well as for studying 
the effects of nicotine on pulmonary function.  
Nicotine is the major cigarette constituent that crosses the placenta and 
accumulates in the fetal compartment to influence fetal lung growth and 
development9,28. The transdermal patch as a nicotine delivery method was used for 
several reasons. First, when fitted to the prepared skin area, the patch slowly and 
constantly releases nicotine for at least a 12 hr time period, which closely resembles 
the smoking habit in humans. In contrast, other nicotine delivery techniques such as 
intravenous administration and nicotine releasing subcutaneous pumps are invasive 
and may result in excessive nicotine blood levels which are difficult to control. 
Second, according to several published studies, nicotine metabolism in pregnant 
women is significantly accelerated compared to non-pregnant females and males29. 
Also, pregnant women tend to quit or at least significantly reduce the number of 
cigarettes smoked per day. According to a study published by Peacock et al., 
pregnant women who smoked during the last trimester of pregnancy most frequently 
had cotinine plasma levels ranging from 15-75 ng/ml30. Similar levels were present in 
maternal blood in this study. In addition, depending on cigarette brand and strength, 
this plasma cotinine level would be equivalent to 2–6 cigarettes smoked per day. 
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Lastly, although administering nicotine during the entire length of gestation would 
more closely mimic human behavior, we have chosen to administer nicotine during 
the last six weeks of ovine gestation since this time frame corresponds to the time 
frame of pulmonary surfactant development in fetal lambs31.  
 In conclusion, nicotine exposure during the last trimester of pregnancy in 
sheep is associated with a significant reduction in SP-A gene expression and protein 
level in lambs born pre-term. This finding may have clinical significance and will 
allow us to further investigate RSV infection as a means to address the hypothesis 
that nicotine exposure during pregnancy may increase RSV susceptibility in human 
infants. To our knowledge, there are no publications describing similar animal model 
in lung development research area. In this work we have described an innovative 
animal model that may be used by the broad research community focused on 
neonatal nicotine related pathological processes such as respiratory distress 
syndrome, impaired intra-uterine lung growth, and other pulmonary abnormalities 
during postnatal life. 
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Tables  
 Ewe 1 Ewe 2 Ewe 3 Ewe 4 Ewe 5 Ewe 6 
6 hr 79 47 52 51 40 30 
12 hr 73 45 41 33 35 <25 
24 hr 38 28 34 25 25 <25 
       
       
  
Table 1. The cotinine plasma levels (CPL) measured in the maternal plasma 6, 12 
and 24 hr after the patch placement in 6 ewes. The CPL is expressed in ug/ml.  
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Figures  
 
Figure 1. The relative SP-A mRNA and SP-D mRNA expression in PTC and FTC 
lambs as well as PTN and FTN lambs. The FTC and PTC values are equal to one. 
The PTN and FTN values are presented relative to the corresponding controls. The 
SP-A mRNA expression is significantly reduced (p=0.01) in PTN lambs (n=7 lambs) 
when compared to PTC lambs (n=6 lambs). There is no significant change in SP-A 
mRNA expression between FTN and FTC lambs. Although maternal nicotine 
administration had a tendency to decrease the SP-D mRNA expression in the PTN 
lambs (n=7 lambs) when compared to the PTC (n=6 lambs), this difference was not 
statistically significant (p=0.09). There is no significant change in SP-D mRNA 
expression between FTN and FTC lambs. 
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Figure 2. Representative immunohistochemical detection of SP-A protein in 
bronchial/bronchiolar epithelium of FTC-(A), FTN-(B), PTC-(C) and PTN-(D) lambs. 
Arrows depict epithelial cells with SP-A protein expression. There was no statistically 
significant difference in SP-A level between PTN and PTC group.  
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Figure 3. Representative Western blot detection of the SP-A and SP-D proteins in 
the lung tissue of the PTC and PTN lambs. The SP-A protein bands in PTN group 
are less detectable when compared to PTC group. There is no difference in SP-D 
protein bands between PTN and PTC group.  
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Figure 4. Representative Western blot detection of the SP-A and SP-D proteins in 
the lung tissue of the FTC and FTN lambs. There are no differences in SP-A and 
SP-D protein bands between FTN and FTC groups.  
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CHAPTER 4. EXPOSURE TO ALCOHOL DURING THE LAST TRIMESTER OF 
PREGNANCY ALTERS THE MATURATION AND IMMUNITY 
OF THE FETAL LUNG 
A paper submitted for publication in American Journal of Physiology-Lung  
Cellular and Molecular Physiology  
Tatjana Lazic, Fatoumata B Sow, Albert van Geelen, David K Meyerholz,  
Jack M Gallup, and Mark R Ackermann 
ABSTRACT  
The effects of fetal exposure to ethanol on lungs remain under investigation. 
Previously, we demonstrated that lambs exposed to ethanol during gestation had 
impaired expression of pulmonary surfactant protein-A and respiratory cilia function, 
the two crucial pulmonary innate immune components. In this study, we investigated 
the effects of in utero exposure to ethanol on the maturation and immunity of the 
fetal lung. Pregnant ewes were surgically implanted with an abomasal cannula and 
administered 1 g ethanol/kg (n=8) or water (n=8) five times a week during the last 
trimester of pregnancy. Lambs were delivered prematurely via Cesarean section or 
naturally. Lungs from all animals were assessed for markers of maturation (HIF-1α, 
HIF-2α, HIF-3α, panVEGF, VEGFR-1, VEGFR-2, glycogen, collagen) and immunity 
(cytokines and chemokines). Pre-term animals exposed to ethanol had significantly 
reduced panVEGF mRNA (p=0.066) and protein levels, HIF-1α (p=0.055), HIF-2α 
(p=0.019), VEGFR-1 (p=0.088) and VEGFR-2 (p=0.067) mRNA levels, but no 
changes in HIF-3α mRNA. In contrast, such changes were not observed in full-term 
animals exposed to ethanol. Similarly, glycogen levels were significantly higher in 
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pre-term animals exposed to ethanol (p<0.01) but not in full-term animals. Pre-term 
animals exposed to ethanol had significantly reduced TNF-α (p=0.05), IL-10 
(p=0.03), CCL5 (p=0.017) and MCP-1 (p=0.0004) mRNA. In full-term animals 
exposed to ethanol, the immune alterations were either sustained (TNF-α, p=0.009; 
IL-10, p=0.03) or returned to control levels (CCL5 and MCP-1). The 
ethanol-mediated alterations in fetal lung maturation and immunity may explain the 
increased incidence of respiratory infections in neonates exposed to ethanol in 
utero.  
INTRODUCTION 
Alcohol (ethanol) consumption during pregnancy has been associated with adverse 
health effects in the developing fetus including premature birth, low birth weight, 
multiple birth defects, and neurodevelopmental disorders, together named Fetal 
Alcohol Spectrum Disorder (FASD) (42). Along these well documented health 
consequences, there have been a few reports suggesting that fetal alcohol exposure 
has detrimental effects on the developing fetal lung, such as suppressed pulmonary 
innate immunity (52), and an increased incidence of neonatal upper respiratory 
infections (11). Despite the evidence that exposure to a low dose of alcohol may 
have harmful effects on the developing fetus, alcohol consumption remains a 
common behavior among pregnant women (46) with one out of 29 pregnant women 
consuming alcohol during pregnancy (14). Moreover, the well-described risks of 
alcohol use during pregnancy remain underestimated because many newborn 
infants exposed to varying levels of alcohol in utero do not display typical clinical 
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symptoms of FASD (37, 38) suggesting a need to widen the research area of 
alcoho--related fetal adverse health effects.  
          Although a few studies have looked at the effects of alcohol on lung growth 
and maturation (36, 52), more studies are needed to address the consequences of 
maternal alcohol use on both pre-natal and post-natal lung function, maturation, and 
immune status. Previously, we developed an ovine model of alcohol exposure in 
utero by administering moderate levels of alcohol to pregnant ewes during the last 
trimester of pregnancy (36). In that study, the maternal blood alcohol levels achieved 
in pregnant sheep were similar to those of individuals who consume alcohol in 
moderation (6, 36). Exposure to alcohol had dramatic impact on the fetal lung, as 
indicated by the reduction in the expression of pulmonary surfactant-A (SP-A) mRNA 
in pre-term born lambs, the decreased protein expression of SP-A in full-term lambs, 
and the reduced ciliary beat frequency in full-term lambs. Recently, another group 
has used a similar ovine model to demonstrate additional alterations in fetal lung due 
to alcohol exposure in utero (52). Although alcohol has deleterious effects on the 
fetal lung, the exact mechanisms by which alcohol alters pulmonary SP-A and other 
immune parameters have yet to be determined. 
          One mechanism by which alcohol can impede with lung development and 
function is through alterations in the expression of growth factors which are vital for 
lung development (15). Fetal lung development is a complex process which is tightly 
regulated, in part by hormones and growth factors (29) such as vascular endothelial 
growth factor (VEGF) (3). VEGF is crucial for pre-natal and post-natal lung 
development as it stimulates angiogenesis and vascular permeability (16, 17). 
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VEGFR blockade results in inhibition of angiogenesis and alveolar formation in the 
developing rat lung (33), and VEGF gene deletion results in less complex alveolar 
patterning (22). Furthermore, VEGF is essential in pulmonary epithelial cell 
maturation and pulmonary surfactant production, as inhibition of VEGF in fetal mice 
results in respiratory distress syndrome (RDS) due to decreased pulmonary 
surfactant production (12).  
          VEGF belongs to a super-family composed of five structurally similar but 
functionally different members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental 
growth factor (PLGF) (58). The VEGF-A family is primarily involved in vascular 
development in various organs including lung, and hereafter will be designated as 
VEGF. VEGF is encoded by a single gene composed of 8 exons and 7 introns (58). 
Due to alternative splicing, this single gene encodes for several isoforms which differ 
in the number of amino acid residues present in the molecule. There are 7 human 
isoforms which contain 121, 145, 148, 165, 183, 189, and 206 amino acid residues 
(39); 4 analog murine isoforms which contain 120, 144, 164, and 188 amino acid 
residues (16); and 3 analog ovine isoforms composed of 120, 164, and 187 amino 
acid residues (10). The VEGF molecules are therefore named as VEGFxxx in which 
xxx subscript refers to the number of amino acid present in the molecule. There are 
several studies which report that the most significant VEGF isoforms in the lung are 
VEGF120 and VEGF164 (34). The term “pan VEGF” and “VEGF-A” are 
interchangeably used since antibodies that can bind and detect multiple VEGF-A 
isoforms are named as “pan-VEGF” antibodies (2).  
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          The VEGF gene transcription is up regulated by 3 transcription factors: 
hypoxia inducible factor-1α, 2α, and 3α (HIF-1α, HIF-2α, HIF-3 α respectively) (17, 
45). All of these transcription factors are expressed in the lung, and loss of HIF-1α 
(49) and HIF-2α (12) in mice is lethal due to impaired alveolar epithelial cell 
maturation and inadequate surfactant production. VEGF binds two related, tyrosine 
kinase receptors: VEGFR-1 (also known as fms-tyrosine kinase-1 receptor (Flt-1) in 
rodents) and VEGFR-2 (also known as kinase insert-domain-containing receptor in 
humans (KDR) or fetal liver kinase-1 receptor (Flk-1) in rodents). VEGFR-2 has 
been considered as a main VEGF signaling receptor (56). VEGFR-1 functions as a 
decoy receptor as it undergoes weak tyrosine autophosphorylation upon VEGF 
activation (17). Both of these receptors have been detected in the lung; VEGFR-2 is 
detected in the ATII cells and, when activated, enhances ATII cellular growth and 
surfactant synthesis (12).  
          There are very few studies that focus on the direct effect of alcohol on VEGF. 
It has been reported, however, that chronic alcohol exposure down regulates nitric 
oxide system and VEGF expression by blood vessel endothelial cells resulting in 
systemic hypertension in rats (31). In addition, acute alcohol intoxication has been 
associated with increased morbidity and mortality in traumatic injuries (5). Although 
the precise mechanism by which alcohol influences the post-traumatic outcomes is 
not known, there are some speculations that alcohol alters the VEGF signaling and 
slows down angiogenesis and, therefore, wound healing (44). To the best of our 
knowledge, this is the first study analyzing the effect of alcohol on VEGF in the 
developing fetal lung.  
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          As VEGF and the factors HIF-1α, HIF-2α, and HIF-3α are known to have key 
roles in lung function and maturation, and as there is evidence of the deleterious 
effects of alcohol on lung function, development, and immunity, we tested four 
hypotheses: 1) Maternal alcohol ingestion during the third trimester of pregnancy will 
significantly alter lung maturation through reduced expression of HIF-1α, HIF-2α, 
HIF-3α and their downstream target genes VEGF, VEGFR-1 and VEGFR-2;  2) 
Maternal alcohol ingestion during the third trimester of pregnancy will significantly 
alter lung maturation by affecting lung glycogen and collagen contents; 3) 
Alcohol-related lung development alterations will be more severe in pre-term animals 
than full-term animals; and 4) Compared to control animals, those exposed to 
alcohol in utero will display dysregulated expression of genes involved in host 
defense and the inflammatory response. 
MATERIALS AND METHODS 
Experimental procedure 
Animal use and experimental procedures were approved by Iowa State University’s 
Animal Care and Use committee according to the requirements of the NIH guide for 
the Care and Use of Laboratory Animals. Sixteen mixed (1/2 Rambouillet, 1/4 
Dorset, and 1/4 Finsheep) date-mated, pregnant ewes were assigned in four groups: 
alcohol exposed pre-term and full-tem groups and control pre-term and full-term 
groups. Alcohol was administered through surgically implanted abomasal cannula. 
This procedure was previously described in detail (36).  Ewes assigned to alcohol 
groups received 40% ethanol at 1gr/kg, V/V (Sigma, St. Louis, MO). Control ewes 
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received the equivalent amount of water. The ewes received alcohol or water five 
days a week for five weeks. Serum alcohol (ethanol) concentrations (SAC) were 
determined at 6, 12 and 24 hours post a single infusion by headspace gas 
chromatography analysis (University of Iowa Diagnostic Laboratories, Iowa City, IA). 
The lambs in the pre-term group were delivered via Cesarean section at 138 days of 
gestation (term is ~147 days). The lambs in the full-term group were allowed to 
delivered naturally (~147 days); there were a total of twenty-four lambs, and we 
assigned six lambs to each group (n=6). After lambing or uterotomy, all lambs were 
euthanized by intravenous administration of sodium pentobarbital. The lung samples 
from the lateral portions of the right cranial lobes were collected into cryovials, snap 
frozen in liquid nitrogen and stored at -80°C until RNA extraction for qPCR analysis 
or protein extraction for Western blot analysis. The remaining tissue from the same 
lung lobes were fixed in 10% buffered formalin, processed, and embedded in 
paraffin from which 3 micron thick sections were cut for periodic acid-Schiff (PAS) or 
Gomori’s trichrome special staining procedures.  
Gene expression analysis 
The fluorogenic real-time quantitative polymerase chain reaction analysis (qPCR) 
was used to measure alcohol-mediated changes in gene expression of pulmonary 
maturation markers; HIF-1α, HIF-2α, HIF-3α, panVEGF, VEGFR-1 and VEGFR-2, 
and gene expression of major groups of immune genes in the lung including the 
pro-inflammatory cytokine; tumor necrosis factor (TNF)-α, the anti-inflammatory 
cytokine; interleukin (IL)-10, chemokine (C-C motif) ligand 5 (CCL5), and monocyte 
chemotactic protein (MCP-1). This procedure has been previously described in detail 
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(36). Briefly, total RNA was isolated from lung tissues sampled from lateral portions 
of the right cranial lobe, followed by DNase treatment (TURBO DNA-free kit, 
Ambion, Austin, TX).  A test plate for all targets was run to determine the optimal 
sample dilution. The DNase treated RNA isolates were diluted 1:10 with 
nuclease-free water, then diluted to their ideal ranges (according to what was 
learned from the test plate analysis) and placed in duplicate into 96-well qPCR 
reaction plates (Applied Biosystems Incorporated, Forest City, CA). Each sample 
contained 7.8 μl of DNase-treated, appropriately-diluted RNA isolate, 15 μl of a 
commercially available Applied Biosystems One-Step Master Mix, 1000 nM primers, 
150 nM TaqMan (5’-6FAM, 3’-TAMRA-quenched) probe and nuclease-free water. 
The negative, no-template control wells contained nuclease-free water (Ambion) 
instead of RNA isolate. Twenty-seven μl of each reaction was used in-well in the 
96-well reaction plates. The plates were run in the GeneAmp 5700 Sequence 
Detection System (Applied Biosystems, Foster City, CA). The results were analyzed 
by using the GeneAmp 5700 software and departmentally available Excel files.  
Western blot analysis 
The western blot analysis was used to measure panVEGF protein levels. The term 
“pan VEGF” and “VEGF-A” are interchangeably used since antibodies that can bind 
and detect multiple VEGF-A isoforms are named as “pan-VEGF” antibodies (2). The 
sections of the lateral portion of the right cranial lung lobes (0.1 g) were 
homogenized in 2 ml T-PER® Tissue Protein Extraction Reagent (Pierce, Rockford, 
IL) and Complete TM Protease Inhibitor Cocktail (Santa Cruz Biotechnology, Santa 
Cruz, CA). The tissue homogenates were centrifuged at 13,000 x RPM for 5 minutes 
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at 4o C, protein extracts were boiled for 5 minutes with sodium dodecyl sulfate (SDS) 
sample buffer, loaded onto polyacrylamide gel (PAG, 8-16%, Precise TM Protein 
gels, Thermo scientific, Rockford, IL) and then transferred to polyvinylidene fluoride 
transfer membrane (PVDF transfer membrane, Millipore, Bedford, MA). The 
membranes were then blocked with 5% nonfat dry milk and incubated overnight at 
4°C with the mouse monoclonal anti recombinant VEGF 189 protein antibodies 
(Santa Cruz Biotechnology, Santa Cruz, CA). The next day, the membranes were 
incubated for 90 minutes at room temperature with secondary Alexa Fluor 488 goat 
anti mouse normal IgG antibodies (Invitrogen, Carlsbad, CA). To demonstrate the 
equal loading of the protein samples, the proteins were stripped and the membranes 
were probed with monoclonal mouse anti β-actin antibodies (Sigma, St. Louis, MO) 
and secondary antibody goat anti mouse Alexa fluor 488. The fluorescence was 
detected by using Typhoon imaging system (GE Healthcare,Baie d’Urfe, Quebec, 
Canada) using excitation wavelength 488 and 520 BP 40 emission filter. 
Staining and microscopic scoring of cytoplasmic glycogen  
To determine the glycogen content in type II pneumocytes, the slides were subjected 
to the periodic acid-Schiff stain (PAS) procedure as follows: upon collection, the lung 
tissue was fixed in 10% buffered formalin for 24 hours and 3 μm-thick tissue sections 
were cut and placed on glass slides. The slides were then deparaffinized, 
rehydrated, and placed in 1% periodic acid for 10 minutes (Sigma, St. Louis, MO) 
followed by a thorough wash. After the wash, slides were placed in Sigma Schiff’s 
reagent (Rowley Biochemical Institute, Denver, MA) for 15 minutes followed by 
another wash after which they were counterstained with MCB reagent 
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(Manufacturing Chemists, Inc, Gibbstown, NJ), rinsed in distilled water, dehydrated 
and cover-slipped using Permount (Fisher, Hanover, IL). Ten alveoli were scored 
within one tissue section from each lamb. Alveoli were similar in size which ranged 
between 100–200 μm in diameter. Scoring was based on predetermined scale: 0, no 
detectable stain; 1, earliest detectable stain; 2, cytoplasmic glycogen granules 
present in less the 30% of alveolar epithelial cells; and 4, cytoplasmic glycogen 
granules present in more than 60% of alveolar epithelial cells.  
Staining and microscopic scoring of alveolar collagen  
To determine the content of collagen within the alveolar walls, the slides were 
subjected to Gomori’s trichrome stain procedure which stains for type I and type III 
collagen. The procedure was performed as follows: the lung tissue fixed in 10% 
buffered formalin for 24 hours was cut in 3 μm-thick sections and placed on glass 
slides. The slides were then deparaffinized, rehydrated, and placed in Picric Acid 
solution for 30 minutes followed by a through wash in running tap water for 10 
minutes after which they were rinsed in distilled water and placed in Gomori’s 
trichome stain for 15 minutes. After the staining, the slides were placed in 0.5% 
glacial acetic acid and then dehydrated and cover-slipped using Permount (Fisher, 
Hanover, IL). 10 alveoli from different fields (50 total) were counted to determine 
which had complete circumferential positive staining for collagen, which had staining 
of >50% of the circumference, and then which had >0 but <50% positive staining of 
the circumference. Staining around the vessels and airways was not taken into 
account. 
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Statistical analysis 
The summary statistics (mean and standard error of the mean) was calculated for 
each experimental group. Student’s t-test was performed using Graph Pad Sigma 
software (San Diego, CA). One-way ANOVA was performed using SAS version 9.1 
(SAS Institute, Cary, NC). Mean values of relative mRNA expression levels of genes 
from pre-term and full-term animals exposed to ethanol were compared to control 
animals of the same age group at *p ≤ 0.1, **p≤0.01, and ***p≤0.001 and expressed 
as means ± SEM.  
RESULTS 
Pulmonary HIF, panVEGF and VEGFR gene expression: Compared to control 
animals, the pre-term animals exposed to ethanol had significantly decreased 
expression of HIF-1α (p=0.055), HIF-2α (p=0.0187) (Fig.1), panVEGF (p=0.066) 
(Fig. 2), VEGFR-1 (p=0.088) and VEGFR-2 mRNA (p=0.067) (Fig.3); no significant 
changes were seen with HIF-3α. In full-term animals exposed to ethanol, no 
significant changes in the expression of HIF-1α, HIF-2α, panVEGF, VEGFR-1 and 
VEGFR-2 mRNA were seen when compared to animals of the same age group.   
Pulmonary cytokines and chemokines gene expression: Pre-term animals exposed 
to ethanol had significantly reduced levels of TNF-α mRNA (p = 0.05), IL-10 mRNA 
(p = 0.03), CCL5 mRNA (p = 0.017) and MCP-1 mRNA (p = 0.0004) when compared 
to control animals of the same age group (Fig.4). In full-term animals exposed to 
ethanol, a significant decrease in the expression of TNF-α mRNA (0.009) and IL-10 
mRNA (0.03) was observed.  However, no significant changes in the expression of 
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CCL5 mRNA (p = 0.12) and MCP-1 mRNA (p = 0.33) occurred when compared to 
control full-term animals.  
Pulmonary panVEGF protein levels: The western-blot analysis demonstrated 
significantly decreased levels of panVEGF protein in the lungs of pre-term animals 
exposed to ethanol when compared to control animals of the same age group (Fig. 
5). 
Pulmonary glycogen content: We found that pre-term animals expressed more 
glycogen in their lungs when compared to full-term animals (Fig. 6). In addition, the 
increased glycogen retention in the lungs of preterm animals was more pronounced 
and statistically significant when the animals were exposed to ethanol (p<0.01) in 
utero during the last trimester of gestation. In newborn lambs, exposure to ethanol 
did not lead to statistically significant differences in glycogen levels when compared 
to control animals of the same age group. 
Pulmonary collagen content: We found that in utero exposure to ethanol led to a 
statistically significant deposition of collagen in the lung of full-term animals (p = 
0.03) (Fig. 7). Although some collagen deposition was also observed in the lungs of 
pre-term animals exposed to ethanol, the changes were not statistically significant. 
DISCUSSION  
Studies on the detrimental effects of maternal ethanol (alcohol) on the developing 
fetus are of utmost importance. The goals of this study were: 1) to determine a 
mechanism behind alcohol-mediated alterations in lung maturation, and 2) to 
investigate the effects of in utero alcohol exposure on fetal and neonatal pulmonary 
immunity. 
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Lung maturation 
          The current study demonstrated that a potential mechanism of alcohol 
(ethanol)-mediated alterations in lung maturation is through a decrease in the 
expression of panVEGF (includes all VEGF isoforms in the lung), its receptors 
(VEGFR-1, VEGFR-2), and its regulatory components (HIF-1 α, and HIF-2α) and 
through an increase in glycogen retention in lungs. This study demonstrated that the 
effects of ethanol on the fetal lung are more pronounced in pre-term animals than 
animals that have reached full gestation (full-term animals). This may explain our 
previously reported decrease in SP-A mRNA expression in pre-term lambs exposed 
to alcohol in utero (36). VEGF mediates conversion of glycogen in type II 
pneumocytes (ATII) into surfactant proteins (12) and increased glycogen content in 
the lung of pre-term lambs exposed to alcohol most likely resulted from the 
suppressing effect of alcohol on panVEGF mRNA and protein. The most recent 
study done by Sozo et al. demonstrated similar effect of alcohol on the fetal lung. In 
that study, pre-term lambs chronically exposed to alcohol had SP-A and SP-B 
mRNA levels decreased to one third of control levels (52). The exact mechanism by 
which alcohol impairs lung maturation in neonates is not clear; however it has been 
demonstrated that alcohol impairs fetal growth and maturation in general by multiple 
mechanisms. First, alcohol reduces fetal oxygenation and nutrient transport by 
reducing blood supply to the fetus (51). Second, inter-uterine alcohol exposure alters 
growth factors such as growth hormone and insulin-like growth factors-binding 
proteins (15) both of which may impair lung development. Third, there is growing 
evidence that alcohol depletes protective, anti-oxidative enzymes in the fetal lung, 
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thus increasing oxidative stress and damage of the pulmonary epithelial cells, as 
seen in ATII cells (8). Together, these studies indicate that the alteration of fetal lung 
maturation by alcohol is most likely multi-factorial. More recent studies have pointed 
to the impairing properties of alcohol on the HIF-VEGF-VEGFR pathway in cell lines; 
on the nitric oxide system and the expression of VEGF by blood vessel endothelial 
cells (31); and on proliferative wound healing in mice (44). In this current study, we 
looked at additional factors behind the alcohol-mediated alterations on the fetal lung, 
namely the roles of VEGF, VEGFR-1, VEGFR-2, HIF-1α, HIF-2α, and HIF-3α on 
pre-natal and post-natal lung development and maturation in consequence to 
maternal alcohol use. Our finding that fetal exposure to alcohol during the last 
trimester of gestation significantly reduced the expression of factors including HIF-1α 
and VEGFR-2 in pre-term lambs is in agreement with those of Radek et al., who 
demonstrated that acute exposure of endothelial cell cultures to alcohol decreased 
HIF-1α protein level as well VEGFR-2 (43). A study conducted on chick embryos 
demonstrated a dose-dependent decrease of VEGF, Flt-1 and Flk-1 mRNA 
expression following alcohol exposure in area vasculosa, suggesting a mechanism 
by which alcohol impairs embryonal development (55). However, other studies have 
shown the opposite effects of alcohol on VEGF expression. In models of 
pathological conditions such as chick embryo chorioallantoic membrane that bore 
human fibrosarcoma, alcohol exposure increased VEGF expression and thus 
stimulated tumor angiogenesis, growth and metastasis (26). In mice chronically 
exposed to alcohol in utero and post-natally up to weaning, alcohol increased VEGF 
protein levels in the liver and had a tendency to decrease VEGF protein levels in 
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hippocampus (18). In another study done on mice implanted with B16F10 cells 
(melanoma cells), chronic alcohol exposure resulted in significant increases in the 
expression of VEGF mRNA and protein as well as Flt-1 protein level in melanoma 
cells, suggesting progression of melanoma angiogenesis and growth (54). The 
observed differences could be attributed to the fact that in these studies different 
animal models were used. Furthermore, VEGF was often evaluated in neoplastic 
cells in which the gene expression does not parallel the gene expression of 
physiologically normal cells. 
          The well documented role of VEGF during fetal lung development involves 
stimulation of endothelial cell proliferation and suppression of endothelial cell 
apoptosis and therefore stimulation of the blood vessel branching and growth (58). 
However, there are studies suggesting that in addition to blood vessel growth, VEGF 
coordinates the development of other pulmonary tissues and cells such as airways 
and airway epithelial cells; particularly ATII. The major source of VEGF in the lung is 
ATII cells (1) and in the adult human lung, VEGF levels are higher in the 
bronchoalveolar lavage fluid than in the blood (35). These data suggest that ATII 
cells auto-regulate their function by releasing VEGF into the alveolar lumen. 
Incubation of fetal human lung explants with VEGF165 resulted in increased size and 
epithelialization of the distal airway ducts (7). The same treatment increased ATII 
cell differentiation, SP-A and SP-C mRNA levels and SP-A protein level in ATII cells. 
The exact mechanism by which VEGF exerts its effect on ATII cells is not known; 
however, in one study, isolated fetal ATII cells incubated with recombinant VEGF165 
failed to increase transcript levels of SP-A and SP-C which suggested an indirect 
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effect of VEGF exerted by reciprocal paracrine interactions of other lung cell types 
(47). Furthermore, inhibition of VEGF resulted in impaired lung maturation and fatal 
respiratory distress syndrome (RDS) in mice (12). The same study suggested that 
VEGF stimulates conversion of glycogen stores in ATII cells into surfactant proteins 
and treatment of prematurely born mice with VEGF prevented respiratory distress 
and death. These results are in accordance with our finding that the lungs of pre-
term lambs contained more abundant glycogen stores within type II alveolar cells, 
indicating suppressed conversion of glycogen to surfactant proteins due to reduced 
maturation/differentiation. In addition to RDS, decreased expression of VEGF is 
associated with bronchopulmonary dysplasia (PBD) in human infants (3).  
          The main regulators of VEGF gene expression in the lung are hypoxia-
inducible transcription factors; HIF-1α, HIF-2α and HIF-3α (17, 45). In response to 
hypoxic conditions such as intra-uterine environment during gestation, HIF binds 
hypoxia response element on the VEGF promoter and up-regulate or down-regulate 
the VEGF gene transcription. HIF-1α and HIF-2α stimulate expression of VEGF and 
blood vessel formation; in contrast the splice variant of HIF-3α gene known as 
Inhibitory Per/Arnt/Sim (IPAS) has no endogenous transactivation function and has 
been reported to be a negative regulator of VEGF (45). The data on HIF-3α are 
limited; however, in contrast, there are several reports indicating that HIF-1α and 
HIF-2α are crucial for normal intrauterine lung development. For example, HIF-1α-/- 
mice embryos die in utero due to insufficient blood vessel formation (32). In another 
study done on mice, deletion of HIF-1α gene 8 days prior to parturition resulted in 
100% mortality rate of pups. Deletion of the same gene 4 to 6 days prior parturition 
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resulted in 15% survival rate; however, these pups died within hours of parturition 
exhibiting decreased expression of VEGF, HIF-2α and absence of pulmonary 
surfactant proteins (49). HIF-2α knock-out mice can survive to term gestation but 
succumb to severe respiratory distress due to inhibition of VEGF and consequently 
inadequate pulmonary surfactant production (12). Furthermore, study done on lambs 
reported that premature birth and RDS is associated with decreased expression of 
both, HIF-1α and HIF-2α in the lung (25). Although the biological roles of HIF-1α and 
HIF-2α in the lung development are compatible, there are some indications that 
HIF-2α may be more significant in VEGF regulation. For example, in the fetal human 
lung, HIF-1α protein is expressed in the airway epithelium throughout the gestation 
(45). In contrast, HIF-2α is primarily detected in the pulmonary interstitium during 
early gestational stage while during the later gestational stages; its expression was 
detected in interstitium and pulmonary epithelium, primarily ATII cells. While 
expression of HIF-1α remained constant regardless of gestational age, HIF-2α 
mRNA expression increased with gestational age and showed positive correlation 
with VEGF mRNA expression.  
          VEGF binds 2 tyrosine kinase receptors, VEGFR-1 and VEGFR-2. Upon 
activation, VEGFR-2 on endothelial cells mediates endothelial cell survival, 
proliferation, nitric oxide synthesis and increases vascular permeability (56). In 
contrast, activation of VEGFR-1 by VEGF ligand triggers weak phosphorylation of 
the receptor and weak activation of downstream signaling (56). Furthermore, 
targeted mutation of tyrosine kinase domain of VEGFR-1 in mice did not result in 
any over defects during embryonal development (30) whereas targeted deletion of 
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VEGFR-2 gene results in embryonal death due to inadequate vasculogenesis and 
angiogenesis (50). Therefore VEGFR-2 is considered to be the positive regulator of 
VEGF biological activity whereas VEGFR-1 is considered as “decoy” receptor which 
prevents VEGF from binding to VEGFR-2.  Hypoxia up-regulates expression of both 
VEGFR-1 and VEGR-2 genes. It is reported that up regulation of VEGFR-1 gene is 
mediated by HIF-1α in human umbilical vein endothelial cells when exposed to 
hypoxic conditions (21); TNF-α regulates expression of VEGFR-2 gene in human 
endothelial cells in hypoxic conditions (41). Both receptor genes are expressed in 
the lung, although in areas along endothelial cells, VEGFR-2 gene is expressed on 
the surface of ATII cells and, when VEGFR-2 is activated, it enhances ATII cellular 
growth and surfactant synthesis (12). In our studies, we suspect that fetal alcohol 
exposure may have a direct down-regulating effect on the expression (transcription 
or protein stabilization) of HIF-1α and HIF-2α, which consequently leads to the down 
regulation of VEGF and VEGFR expression. Another possible mechanism involves 
increased oxidative stress by alcohol in the fetal lung which accelerates apoptosis, 
especially in the ATII (7) cells which are the main source of VEGF protein in the 
lung. Additional studies are required to further elucidate the underlying mechanistic 
basis for these findings.  
          Pulmonary parenchymal elastic tissue which includes collagen supports lung 
function during inspiration and expiration. The amount of the deposited collagen 
fibers represents a crucial structural component of the lung since decreased 
collagen content results in pulmonary emphysema (57) while increased collagen 
content results in restricted pulmonary function described in pathological conditions 
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such as bronchopulmonary dysplasia (BPD) and asthma (9). Chronic alcohol 
consumption in adults is associated with increased incidence of lung injury in 
patients with sepsis or trauma (27) which has been attributed in part to the increased 
expression of profibrotic growth factors in the lung (28). So far, there has been only 
one report describing the effect of alcohol exposure on collagen deposition in the 
developing fetal lung (52). Sozo et al reported an increased collagen deposition in 
lungs of pre-term lambs exposed to alcohol in utero (52). Although we could not find 
statistically significant differences in the lung collagen content of the pre-term lambs 
exposed to alcohol, those of full-term animals exhibited a significant increase in the 
deposition of collagen. The difference in collagen content in pre-term animals in our 
study and that of Sozo et al may be attributed to experimental procedures: duration 
of alcohol administration to the pregnant ewes was longer and alcohol was infused 
directly into the maternal systemic circulation reaching higher maternal blood 
concentration. Whether the increased collagen deposition in animals that have 
reached full gestational age can detrimentally affect lung function and whether such 
defects will persist with age warrants further investigations.  
Lung immunity  
          This study also demonstrated that: 1) alcohol readily passes through the 
placenta of the ewe and is able to affect the cytokine and chemokine system of the 
fetal lamb, 2) the immune system of the fetal lamb is responsive at the time of birth, 
3) alcohol significantly altered the expression of genes that are crucial to the host 
defense, and 4) the dysregulation of immune genes occurred in both, pre-term and 
full-term animals. Recent research has shown that exposure to alcohol can impair 
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the development and function of immune cells, including reduced T cell development 
in the thymus (24, 48), reduced B cell development in the liver (4, 40) and impaired 
macrophage function (19). Alcohol exposure has other suppressive effects on the 
immune response, such as decreased surfactant synthesis and pro-inflammatory 
cytokines (13, 23) and impaired response to a bacterial challenge (20). Our findings 
that maternal alcohol alters the expression of genes that are crucial to host defense 
and the regulation of the inflammatory response in pre-term animals are in 
agreement with those of Sozo et al. (52) who looked at pro-inflammatory cytokines. 
However, we extended our studies by analyzing the effects of ethanol on lung 
immunity in lambs that have reached full-term gestation and by comparing their 
immune response to that of pre-term animals. In pre-term animals exposed to 
ethanol, some genes displayed significant alterations in expression that either 
persisted to full-term gestation (as seen with TNF-α and IL-10) or were restored to 
levels similar to those of control animals at full-term gestation (as seen with CCL5 
and MCP-1). As TNF-α and IL-10 are cytokines produced by many cells, including 
antigen presenting cells (APC), the sustained decrease in expression after in utero 
ethanol exposure suggests that ethanol can interfere with the function of APC. Our 
findings that ethanol also decreased the expression of the C-C chemokines CCL5 
and MCP-1 are supported by other studies that showed in vitro suppressive effects 
of ethanol on chemokine production(53). The data presented here clearly suggest 
that ethanol is an immunomodulatory agent. Further investigations will be required to 
determine how long the observed alterations in lung immunity will persist in the 
post-natal period, the mechanisms underlying gene alteration and whether the 
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effects of alcohol on the immune system contribute to the increase in post-natal 
susceptibility to respiratory infections.  
Conclusions 
In conclusion, our study demonstrates a novel mechanism by which alcohol impairs 
fetal lung maturation and which may explain the previously reported decrease in 
SP-A expression by prematurely born lambs. Our study also demonstrated that, in 
addition to effects on developing airways, maternal alcohol has significant 
immunological effects on fetal lambs, and that some of the alcohol-mediated 
alterations persist until full-term gestation. To the best of our knowledge, this is the 
first study to report such findings. Considering the importance of VEGF in fetal lung 
maturation, these results may open a new venue for therapeutic targeting VEGF 
pathways in pediatric patients suffering from deleterious effects of in utero alcohol 
exposure.  
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FIGURES  
 
 
 
Figure 1. Relative mRNA expression of hypoxia inducible factor-1α, 2α and 3α (HIF-
1α, HIF-2α and HIF-3α respectively) in the neonatal ovine lung. Exposure to ethanol 
in utero reduces mRNA expression of HIF-1α and HIF-2α in the lungs of pre-term 
(PT) lambs when compared to the control lambs of the same age group. Such 
changes are not observed in the lungs of full-term (FT) lambs exposed to ethanol in 
utero. No significant changes are seen with HIF-3α mRNA expression levels in both, 
PT and FT lambs. (*p<0.1, significance was established at 90% confidence interval). 
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Figure 2. Relative mRNA expression of vascular endothelial growth factor 
(panVEGF) in the neonatal ovine lung. Exposure to ethanol in utero reduces mRNA 
expression of panVEGF in the lungs of pre-term (PT) lambs when compared to the 
control lambs of the same age group. Such changes are not observed in the lungs of 
full-term (FT) lambs exposed to ethanol in utero. (*p<0.1, significance was 
established at 90% confidence interval).  
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Figure 3. Relative mRNA expression of vascular endothelial growth factor receptor 1 
and 2 (VEGFR-1 and VEGFR-2 respectively) in the neonatal ovine lung. Exposure to 
ethanol in utero reduces mRNA expression of VEGFR-1 and VEGFR-2 in the lungs 
of pre-term (PT) lambs when compared to the control lambs of the same age group. 
Such changes are not observed in the lungs of full-term (FT) lambs exposed to 
ethanol in utero. (*p<0.1, significance was established at 90% confidence interval).  
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Figure 4. Relative mRNA expression of chemokines and cytokines, in the neonatal 
ovine lung. Exposure to ethanol in utero reduces mRNA expression of; tumor 
necrosis factor (TNF)-α; (A), interleukin (IL)-10; (B), chemokine (C-C motif) ligand 5 
(CCL5; E)and monocyte chemotactic protein (MCP-1; D) in the lungs of pre-term 
(PT) lambs when compared to the control lambs of the same age group. In the lungs 
of full term (FT) lambs, ethanol exposure in utero reduces mRNA expression of; 
TNF-α; (A) and  IL-10; (B). (*p<0.1, significance was established at 90% confidence 
interval). 
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Figure 5. Vascular endothelial growth factor (panVEGF) protein levels in the lung of 
pre-term lambs. Exposure to ethanol in utero reduces panVEGF protein level in the 
lungs of pre-term lambs when compared to the control lambs of the same age group. 
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Figure 6. Periodic acid-Schiff (PAS) stain for glycogen granules in the type II 
pneumocytes (ATII). Glycogen granules in the ATII are more abundant in the pre-
term lambs exposed to ethanol in utero (B) when compared to the to the control 
lambs of the same age group (A). Glycogen content in the ATII is similar in the full-
term lambs exposed to ethanol in utero (D) and the control lambs of the same age 
group (C).  
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Figure 7. Gomori’s trichrome stain for collagen deposition in the alveolar walls. 
Collagen fibers are more abundant in the alveolar walls of full-term lambs exposed 
to ethanol in utero (D) when compared to the control lambs of the same age group 
(C). Collagen deposition is similar in the pre-term lambs exposed to ethanol in utero 
(B) and the control lambs of the same age group (A). 
 
 
 
 
 
 
 
170
CHAPTER 5. GENERAL CONCLUSIONS 
Experiments performed in our study hopefully reached several important 
milestones, which should have a significant impact on the field of neonatal 
immunology: 
 1. We characterized a new animal model for in-utero exposure to alcohol and 
  determined the effects of in-utero exposure to alcohol during the last 
  trimester of gestation on:  
  a.  fetal tracheal ciliary beat frequency (CBF), and 
  b.  expression of SP-A and SP-D by the fetal lung epithelia. 
 2. We characterized a new animal model for in-utero exposure to nicotine 
  and determined the effect of in-utero exposure to nicotine during the last 
  trimester of gestation on the expression of SP-A and SP-D by the fetal  
  lung epithelia. 
 3. We determined the possible mechanism by which in-utero exposure to  
  alcohol alters the expression of SP-A in the fetal lung.  
Characterization of the New Animal Model of Fetal Alcohol Exposure 
The sheep represents a commonly utilized animal model in research area 
related to the effects of alcohol on the developing fetal lung1,2. This is due to the fact 
that in-utero development of the sheep lung closely parallels the development of the 
lung in humans3. Administration of alcohol directly into the systemic circulation, 
however, significantly alters the physiological metabolism of alcohol4. Our study 
demonstrated that administration of alcohol via abomasal cannula to the pregnant 
sheep allows alcohol to bypass the rumen and avoid degradation by ruminal 
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microflora. We managed to achieve very controlled, but chronic, fetal exposure to 
alcohol in our sheep model, and realistically mimicked clinical situation frequently 
observed in human subjects. Since pregnant women have a tendency to reduce 
alcohol consumption and drink in moderation, by administering alcohol at 1gr/kg in 
the sheep model, the achieved blood alcohol concentration (BAC) was very similar 
to the BAC of humans with moderate alcohol consumption habits5.  
In-utero Exposure to Moderate Levels of Alcohol Alters Fetal Tracheal CBF 
and Expression of SP-A and SP-D by Fetal Lung Epithelia 
Recent studies have indicated that fetal exposure to alcohol alters the 
immune system in the fetal lung and predisposes infants to infections and sepsis6,7. 
Mucociliary apparatus in the airways and pulmonary SP-A and SP-D represent the 
first line defense mechanisms against inspired microorganisms8,9. In this study, we 
demonstrated that in-utero exposure to moderate levels of alcohol during the last 
trimester of pregnancy significantly reduces the tracheal CBF and SP-A gene 
expression and protein levels in the lambs born pre-maturely. The SP-D gene 
expression remained unchanged in both pre-term and full-term lambs. This finding in 
part can explain the increased susceptibility to respiratory infections in neonates 
exposed to alcohol in-utero. Furthermore, our results created a strong basis for 
enhancing recommendations for absolute abstinence from alcohol consumption in 
any stage of pregnancy.  
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Characterization of the New Animal Model of Fetal Nicotine Exposure  
 Cigarette smoke contains thousands of chemicals; different studies have 
demonstrated, however, that immunomodulatory effects of nicotine parallel 
immunomodulatory effects of the whole cigarette smoke10. The sheep is a commonly 
used animal model in research related to the in-utero nicotine effects on the 
developing lung11,12. Previously described nicotine administration techniques, 
however, are invasive and potentially may result in excessive nicotine levels in the 
maternal blood11. In this study, we have developed a new technique of nicotine 
administration by simply applying a nicotine patch on the clipped skin of pregnant 
ewes. By doing so, we have achieved cotinine levels in the maternal blood which are 
similar to the cotinine levels of humans who smoke five to six cigarettes per day13. 
This technique is non-invasive, inexpensive, and avoids the risk of excessive 
administration of nicotine to the pregnant animals.  
In-utero Exposure to Low Levels of Nicotine Alters the Expression 
of SP-A and SP-D by Fetal Lung Epithelia 
Smoking during pregnancy has detrimental health effects in the developing 
fetus14. Neonates exposed to cigarette smoke during fetal development have 
impaired lung function and increased risk of respiratory infections, especially RSV 
infection14,15. In this study, we demonstrated that in-utero exposure to low nicotine 
levels during the last trimester of pregnancy significantly reduces SP-A gene and 
protein expression in prematurely born lambs. The SP-D gene and protein 
expression was not affected by nicotine in both pre-term and full-term lambs. 
Similarly to our previous observation in alcohol exposed neonates, the results of this 
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study may provide a strong evidence against chronic use of nicotine in any form 
during pregnancy (cigarette, nicotine replacement therapy, etc.). Considering that 
nicotine addiction is frequently difficult to control, however, results of our study may 
offer potential guidelines for closer monitoring of neonates born from individuals who 
consumed nicotine in any form during pregnancy. Considering that alcohol and 
nicotine exposure seem to have a significantly negative effect on innate immunity 
protein (SP-A), possible therapeutic strategies targeting regulation and production of 
this protein may have a unique value for effective medical treatment of these 
conditions.    
In-utero Exposure to Moderate Levels of Alcohol Reduces VEGF Gene 
                         Expression and Protein Levels in the Fetal Lung  
In the developing lung, VEGF plays a crucial role in vasculogenesis and 
angiogenesis16. Recent studies, however, indicate that in addition to blood vessel 
formation, VEGF participates in alveolar type II cell maturation and lung surfactant 
production17,18. In this study, we demonstrated that in-utero exposure to moderate 
levels of alcohol during the last trimester of pregnancy significantly reduces VEGF 
gene and protein expression in prematurely born lambs, while VEGF gene 
expression and protein levels were not affected by alcohol in the lambs that have 
reached full gestation. Considering that VEGF is a potent regulator of the lung 
maturation and innate immunity protein production, it is likely that decreased VEGF 
expression may be the first step in the cascade responsible for the abnormal 
neonatal lung function and immunity. Considering that during the last decade, VEGF 
has become a frequently studied and utilized pharmacological target in many 
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systemic diseases (neoplasia, macular degeneration), it is likely that utilization of this 
vast biological and pharmacological knowledge of VEGF biology can be effectively 
used for development of new therapeutic modalities for neonatal lung diseases.  
Future Research Goals 
Our data are strongly suggestive of deficient function of innate immunity 
components in fetal lungs exposed to chronic alcohol, which may open novel 
therapeutic opportunities for prematurely born neonates with respiratory infections. 
Pharmacological targeting of the ciliary motility and pulmonary surfactant proteins 
can be a reasonable strategy for early medical interventions in this particular patient 
population, which could be possibly effectively tested in our animal model in the 
future. We have identified decreased VEGF expression associated with chronic 
alcohol exposure, and manipulation of the VEGF pathway may prove to be a 
potentially successful therapeutic strategy for treatment of respiratory abnormalities 
in prematurely born neonates. Since we successfully demonstrated in the past the 
capacity of the human RSV to infect ovine lungs, the future experiments may provide 
more detailed knowledge about interactions between common infectious agents and 
different components of the neonatal lung immunity affected by chronic alcohol and 
nicotine administration. Considering that size and developmental biology of the 
sheep lung is almost identical to human lungs, it is likely that any effective 
therapeutic modality in the sheep model may become an effective translational step 
toward successful treatment of human patients.     
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